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  The  continuous demand  that  the pharmaceutical and biotech companies are  facing, 
has created  the need  to apply all available  techniques  to decrease attrition  rates, costs and 
the time to market of new drugs. One of the main goal of the drug discovery process  is the 
identification of a  lead compound,  that    it  is  the starting point  for  the development of new 
candidate drugs.[1]   
  In the last two decades, the availability of structural information of a macromolecular 
target  opens  the  door  to  Structure‐Based  Drug  Design  (SBDD).[2]  The  SBDD  exploits  the 
knowledge of the 3D structure of the biological targets and/or their  ligands for the design of 
new  lead  compounds.  In  fact, X‐ray  crystallography and nuclear magnetic  resonance  (NMR) 
have been developed  to a  level where  they are now applied  routinely. This has had a  large 
impact  on  the  number  of  experimentally  determined  molecular  structures  available.  In 
particular,  NMR  spectroscopy  is  greatly  esteemed  for  its  ability  to  elucidate  molecular 
structure, but  its greatest potential  in drug discovery probably  lies  in the  information that  it 
can reveal about molecular  interactions at the atomic  level.[3] This trend  is now seen both as 
an alternative and a complement to the more coarse approach exemplified by the application 
of combinatorial chemistry and high‐throughput screening (HTS). 
  In  fact,  one  of  the most  common  approaches  employed  up  to  now  to  reach  this 
objective  is  the  screening  of  compounds  libraries  of  small molecules:  initial  potential  hit 
compounds  are easily obtained  via,  for example, a  classic high‐throughput  screening  (HTS). 
Usually, once found, the most promising hits must be optimized in order to achieve better in 
vitro activity,  selectivity, pharmacodynamic and pharmacokinetic properties,  that  implicates 
the  synthesis  and  the  testing  of  compound  analogues.  This  involves  a  very  long  iterative 
process;  in  fact, even  if  the achievement of a promising  initial compound  is quite a efficient 
process via HTS, the selection of the “wrong” hit (a false positive) to be taken into subsequent 
steps, may be time consuming and costly.  
  Therefore,  the  development  of  a  robust,  simple  and  general  technique  for  hit 
validation  is  general  needed.  Nuclear  magnetic  resonance  (NMR)  spectroscopy  is  a  very 
powerful  analytical  technique  for  studying  intermolecular  interactions  and  is  unique  in  its 
ability  to  provide  information  on  the  structural,  thermodynamic  and  kinetic  aspects  of  the 
binding reaction.  It has thus  found widespread use  in the  field of molecular recognition and 
















(FBDD)[3]. This  strategy  consists of building up a  lead  compound  (typically  smaller  than 500 




  Metalloproteins[5]  represent  a  group  of  very  interesting  targets  that  has  been 
extensively studied for the development of new candidate drugs. Several of these proteins are 
important medicinal  target  for  conditions  ranging  from  infection  to  cancer  and metastasis. 
Many  of  this  proteins  present  a  zinc(II)  ion  in  the  active  site:  different  classes  of  small‐
molecule  inhibitors  has  been  designed  to  bind  this  particular  ion  in  the  active  site  of  the 
enzyme. 
  During my  PhD,  I  have  dealt with  design,  synthesis  and  evaluation  of  new Matrix 




  The MMPs, also  called   matrixins, are a  large  family of  structurally  related enzymes 
that mediate the breakdown of connective tissue, and are  important for creating the cellular 
environments  required  during  development  and morphogenesis.  They  are  Ca2+‐  and  Zn2+‐
dependant enzymes  that collectively degrade most of  the component of  the ECM,  including 
collagen,  glycolproteins  and  proteoglycans,  in  the  normal  range  of  pH.[6] MMPs  generally 
consist of a prodomain, a catalytic domain, a hinge region and a hemopexin domain (Figure 1). 














Figure 1. Domain  structure of MMPs. The domain organization of MMPs  is  as  indicated:  S, 


























  Gelatinase A  (MMP‐2) and gelatinase B  (MMP‐9) belong  to  this group. They  readily 
digest  the  denatured  collagens,  gelatins. MMP‐2,  but  not MMP‐9,  digests  type  I,  II,  and  III 
collagens: moreover MMP‐2 in humans is important for osteogenesis. 
Stromelysins   
  Stromelysin  1  (MMP‐3)  and  stromelysin  2  (MMP‐10)  both  have  similar  substrate 






  The matrilysins  are  characterized  by  the  lack  of  a  hemopexin  domain. Matrilysin  1 
(MMP‐7) and matrilysin 2  (MMP‐26), also called endometase,are  in this group. Besides ECM 
components, MMP‐7  processes  cell  surface molecules  such  as  pro–α‐defensin,  Fas‐ligand, 
pro–tumor  necrosis  factor  (TNF)‐α,  and  E‐cadherin. Matrilysin  2  (MMP‐26)  also  digests  a 
number of ECM components. 
Membrane‐Type MMPs 
  There  are  six membrane‐type MMPs  (MT‐MMPs):  four  are  type  I  transmembrane 
proteins  (MMP‐14,  MMP‐15,  MMP‐16,  and  MMP‐24),  and  two  are 













as  a  T‐cell–derived  autoantigen  from  patients with  rheumatoid  arthritis  (RASI).  Enamelysin 
(MMP‐20), which digests amelogenin, is primarily located within newly formed tooth enamel. 











  Several  attempts  to design  selective  inhibitors have been  carried out by using    the 
structure‐based  strategy.[7‐9]  Although  this  strategy  has  been  successfully  applied  in  drug 
discovery against several protein target,[10;11] in case of MMPs the results have been relatively 
disappointing. 
  In  fact,  there  is a extensive  literature available on  the  structure of MMPs and  their 
interaction with inhibitors,[12‐14] that show the binding mode of several inhibitors in the active 
































in Figure 2. CGS‐27023A  (a broad spectrum MMPs  inhibitor) effectively  fills  the available S1’ 
pocket for MMP‐1, but there is additional space available in the stromelysin S1’ pocket. In fact, 
the  design  of  stromelysin  inhibitors  should  for  example  take  advantage  of  this  deeper  S1’ 
pocket by using a biphenyl  substituent  in another  series  instead of  the p‐methoxyphenyl  in 
CGS‐27023A to bind into the S1’ pocket. In addition to the conformational difference between 
the S1’ pockets,  there are  some other  changes  in  the  sequences between  the MMPs  in  the 
active site. 
  Besides the structural differences  in the S1’ pocket, the poor results of the structure‐
based approach  in designing of MMPI  can be  likely due also  to  the poor knowledge of  the 
dynamical  features of  these proteins.[16]  In  fact only  few selective MMPI as  for example  the 
pyrimidine  dicarboxamide MMP‐13  inhibitors  (Figure  3)  have  been  designed  so  far.  In  this 
molecule  the  high  affinity  and  selectivity  for MMP‐13  is  achieved  by  an  optimal  fit  of  the 
inhibitors  into  the  extremely  large  S1’  cavity  and  by  the  large  network  of  interactions  that 




























has been also observed  in MMP‐12 where  internal  conformational adjustments occur upon 
binding of the inhibitor.[19] 
  Complementary  information  can  be  achieved  by  NMR  structures,  where  the  poor 
definition of specific protein regions together with dynamic  information provide evidence of 
internal  flexibility.[20;21]  Recently,  the  active  sites  of  several MMPs  have  been  structurally 
characterized  by  X‐ray  and  NMR  and  in  all  investigated  proteins  exhibits  highly  similar 
structural and dynamical features. A comparative analysis carried out on solution and crystal 




X‐ray  structures  complexed  to  three  different  inhibitors.  The  presence  of  different 
conformations is markedly evident for loop L8, forming the S1’ cavity. 
  In this respect, a further hints to design more potent and selective inhibitors targeted 
to  active  site may be obtained  from  a  large number of  structures of MMP  adducts with  a 
homologous series of ligands, as they can provide information on the extent of the motion of 
each residue upon binding. This strategy  is based on a careful analysis of the structural data, 














at  the  level  of  transcription,  activation  of  the  precursor  zymogens,  interaction  with  ECM 
components,  and  inhibition  by  endogenous  inhibitors.[22]  The  tissue  inhibitors  of 








location of  the  catalytic  site  cleft  is  indicated by  a dashed  rectangle. Within  the  active‐site 







and  their  expression  is  regulated  during  development  and  tissue  remodeling.  Under 
pathological  conditions  associated with unbalanced MMP  activities,  changes of  TIMP  levels 
are considered to be important because they directly affect the level of MMP activity. 
Introduction 




  MMPs are also regulatory molecules,  in fact  inflammatory cytokine or growth factors 
can  regulate  the  expression  of MMPs,  and  the  cytokine  and  their  receptors  can  also  be 
substrate for MMP action. 
  A number of studies[23] have provided evidence  for  the  involvement of  the MMPs  in 
normal  physiology  process  as  wound  repair,  epithelial  remodeling  and  angiogenesis.  But, 
when there is an imbalance in one or more of the regulatory processes, what may occur is an 
overexpression/activation of this proteases. A loss of activity control may lead to the onset of 
important  diseases.  At  first,  the  obvious  destructive  capability  of  MMPs  focused  most 
researches onto diseases that  involve breakdown of the connective tissues  (arthritis, cancer, 
periodontal disease), but MMPs  are  involved  in many other pathologies  as  atherosclerosis, 
aneurysm, nephritis and fibrosis. Moreover, multiple MMPs are overexpressed in a wide range 
of tumors, and especially in tumor cells with significant invasive properties. Aggressive cancer 








  Both  small  molecules  (synthetic  and  natural  products)  and  macromolecular 
endogenous inhibitors (as TIMPs) have been considered as potential therapies for diseases in 
which  excess MMP  activity  have  been  implicated.[24] Unfortunately,  the  therapeutic  use  of 
TIMPs has been  limited by  the  fact  that  they  are proteins:  in  fact  the production, use  and 
administration should be very difficult. The principal approach taken for the  identification of 
synthetic  inhibitors  is  the  substrate‐based  design  of  peptide  derivatives  derived  from  the 
information  of  the  sequence  about  the  cleavage  site;  one  of  the  first  examples  was 
Marimastat (Figure 5).[25] 
Introduction 









































inhibitors  currently  being  studied  are  derived 
from  the  peptide  structure  of  the  α‐chain  of 
type  1  collagen  at  the  point  at  which 
collagenases  first  cleave  the  molecule  (red 











the  active  site  zinc  ion.  After  that,  many  non‐peptide,  highly  potent  inhibitors  has  been 
identified  and  developed;  one  of  the  most  important  classes  was  represented  by  the 









  The binding‐mode of  this  inhibitor with MMP‐12 has been elucidated  through X‐ray 
crystallography;[14]  the  aromatic moiety  interact  with  the  hydrophobic  S1’  pocket  and  the 
Introduction 












Figure 7. X‐ray structure of  the catalytic domain of MMP‐12 complexed NNGH  (A). Only  the 
ligand binding  site  is  shown  for  clarity. Enlargement of  the active  site‐bound NNGH and  its 
interactions with MMP‐12 (B). In B the ligand electron density is also shown. 
 
  This  aryl‐sulfonamide  derivatives  have  been  largely  exploited  to  synthesize  broad‐
spectrum MMP  inhibitors;  these  scaffolds  in  fact  present  different  positions which  can  be 
easily functionalized by introducing new functional groups. Moreover many of them present a 
very high affinity for MMPs. This feature, together with their easy synthetic accessibility and 





  One of  the most  studied MMP  inhibitors  is  the  sulfonamidic hydroxamate MMI270 
(CGS27023A, Novartis) (Figure 2). This broad‐spectrum inhibitor was selected for development 
based  on  its  superior  efficacy  in  a  murine  model  cancer  in  comparison  of  a  number  of 
analogues and because it showed a favorable pharmacokinetic profile. In fact MMI270 is one 
of  the  first  sulfonamidic,  orally  available  inhibitors:  additionally  it  is  rapidly  absorbed  and 
Introduction 






by  introducing  lipophilic  substituents,  decreasing  in  this  way  solubility  in  water  and 
compromising oral bioavailability.  
  MMI270  did  not  show  antiproliferative  activity  against  tumor  cell  lines  in  vitro; 




MMI270 has been beneficial  in preventing or slowing  the  formation of  lung metastases  in a 
preclinical model. MMI270 was generally well tolerated, but the two main toxicities were rash, 
generally  mild,  and  musculoskeletal  side  effects  (general  myalgia/arthralgia  to  severe 
tendonitis with limitation of range of movement in the affected joints).  
  The musculoskeletal syndrome (MSS) is a side effect very common with non‐selective 
inhibitors; this  is probably due to  indiscriminate  inhibition of all kind of zinc endopeptidases, 
that are  involved  in a wide range of normal, physiological processes  in which  inhibition may 
cause excessive matrix deposition leading to fibrosis.  
  The  postulate  that MMP‐1  inhibition  alone  is  responsible  for  the  side  effects was 




that  an  oral MMP  inhibitor,  BAY12‐9566,  that  do  not  inhibit MMP‐1  in  vitro  not  present 
musculoskeletal side effects; however, it was not clinically active either. 
  Unexpected  side  effects  could  also  result  from  the  inhibition  of  currently 
uncharacterized, but essential, MMP‐regulated pathways; the activity of ADAMs (adamalysin, 
a non‐MMP metalloproteinases) could also been affected. The dose of broad range inhibitors, 
on  the  other  hand,  could  be  adjusted  so  that  matrix  destruction  is  prevented  without 
concomitant excessive matrix deposition.[29] Moreover, we don’t know actually  if  the use of 
specific  inhibitor  will  be  possible  in  a  next  future:  for  example,  it  is  not  yet  known  with 
certainty which enzymes are  the key‐players  in  relevant diseases as  rheumatoid arthritis or 










Periostat®  (doxycicline, CollaGenex Pharmaceutical  Inc., an MMPs’ activity  inhibitor used  for 
periodontitis);  it  is  a  derivative  of  the  antibiotic  tetracycline,  but  it  is  effective  at 
subantimicrobial doses.  
  Anyway,  because  of  the  high  therapeutic  potential,  the  improvement  of  MMP 










1) In  particular  I  designed  and  synthesized  a  biotin  chain‐terminated  inhibitors  (BTI) 
showing  high  affinity  for matrix metalloproteinases  (MMPs)  on  one  side  and  high 
affinity  for  avidin  through  the  biotinylated  tag  on  the  other.  The  affinity  of  the 
designed BTI  toward  five different MMPs has been evaluated and  the  simultaneous 






with  symptoms of discomfort.  The MMPs  (in particular MMP‐1,  ‐2,  ‐9  and  ‐13)  are 
highly  involved  in  the  pathogenesis  of  this  disease,  and  they  are  associated  with 
disruption  of  corneal  epithelial  barrier  function  and  corneal  surface  irregularity. 
Therefore an  important  improvement  in  the  treatment of  this disease  could be  the 
use  of  a  non‐selective  MMPI  conjugated  to  different  type  of  dendrimers  for  the 
development of a new drug delivery system able  to sustain  the drug  release and  to 
remain  in  the  vicinity of  the  front of  the  eye  for  as prolonged period of  time.  This 
compounds will be evaluated in the treatment of dry eye syndrome. 
Introduction 




3) The  lack  of  selectivity  and  the  poor  bioavailability  are  the  two major  problem  of 
MMPIs.  In particular,  a  very  interesting medicinal  target  in  the MMPs  family  is  the 
matrylisin (MMP‐7), that it is overexpressed in many human cancer and it contributes 
to  the  invasive growth of  colon  carcinoma. Nevertheless, high affinity and  selective 
inhibitors for this particular MMP are not present in literature. In this contest, we had 
synthesized a new inhibitor that present good water‐solubility and an high affinity for 
MMP‐7,  that will be  tested  in vivo against colon cancer,  in collaboration with Dr. L. 
Vannucci of the University of Prague.  
 




bioavailability problems. The glycosidic residue was  introduced  in a suitable  location 
of  the molecule,  linked  through a spacer of appropriate  length. This  inhibitors are a 
prototype structure that opens the way to the design of a new class of highly effective 
MMPIs. Moreover, we  had  synthesized  a  new  group  of MMPIs  that  presented  an 
hydrophilic residue (for example an alcohol or a diol): we demonstrated not only that 
inhibiting properties was not be affected by the  introduction of this type of residue, 
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drug  design  driven  by  structural  data  is  currently  applied  to  speed  up  the  design  of  new 
candidate drugs in pharmaceutical research.[2‐5] The same approach is even more important to 
design  molecular  probes  where,  besides  classical  requirements,  additive  structural  and 
functional features are required. As we have already seen, expression and activation of MMPs 
are increased in many relevant pathologies, as well as in almost all human cancers, compared 
to  physiological  conditions.  Furthermore,  the  degree  of  overexpression  of MMPs  in  cancer 
tissues is strictly associated with the level of tumor invasiveness and with its tendency to form 
metastasis.  It  is  therefore  apparent  that  the  development  of  efficient  molecular  devices 
designed to reveal the overexpression of MMPs may be a powerful tool for the early detection 
of  tumors  and  the  assessment  of  their  aggressiveness,  as  well  as  of  cardiocirculatory 
problems.[6] 
  Studies  focused  on  the  detection  of  overexpression  of  MMPs  have  already  been 
reported  [7]  and probes  to profile MMPs  in  tissues  synthesized  and  tested.[8;9]  In particular, 
hydrolyzable,  near‐infrared  fluorescent molecules  have  been  successfully  tested  in mice  to 
detect  fibrosarcoma.[10]  Unfortunately,  this  innovative  technique  suffers  from  the  serious 
limitation represented by the limited penetration of light (a few millimeters); such a degree of 
penetration is only sufficient for the readout of superficial subcutaneous tumors (<10 mm).  
  An  interesting approach to detect overexpression of MMP  in atherosclerosis has also 
been published. Low molecular weight inhibitors, able to interact with the active site of MMPs 
involved  in  atherosclerotic  plaque  disruption,  have  been  targeted with  nuclear  agents  and 
tested  in vivo.[11‐13] Although the results reported were extremely encouraging, the approach 
presented  a  scarce  flexibility,  due  to  experimental  difficulties  in  preparing  the  targeted 
inhibitors and to limited availability of suitable nuclear agents. 
  A significant  improvement  in  the development of MMP‐conjugated probes  to detect 
pathological  events  may  be  the  rational  design  of  biotin‐labeled  inhibitors,[14]  capable  of 
binding to MMPs exclusively and with high affinity. These tagged molecules rely on the well‐














in capture processes for a  large number of different application, both  in vitro and  in vivo:  in 
fact the specificity of biotin binding to avidin provides the basis for developing assay systems 
to detect or quantify analytes. 






  The  biotin  interaction  with  avidin  is  among  the  strongest  non‐covalent  affinities 
known, exhibiting a dissociation constant about 1.3 X 10‐15 M. Moreover the biospecificity of 
















bind  particular  antigen molecules.  If  there  are  biotin  labeles  on  the  antibody molecule,  it 
creates multiple sites for binding avidin. If avidin is in turn labels with an enzyme, fluorophore 
etc.,  then  a  very  sensitive  antigen‐detection  system  is  created.  The  simplest  assays design, 
called  the  labeled  avidin‐biotin  system  (LAB),  a  biotinylated  antibody  is  incubated with  its 




















for  example  employing  fluorescently  labeled  avidin molecules  that  can  be  used  to  detect 
biotinylated molecule after it has bound its target. The main application of this technique is in 
cytochemical staining wherein the fluorescent signal is used to localize antigen or receptor in 
cells. Furthermore,  radiolabeled avidin can be employed as a universal detection  reagent  in 

















  In  clinical  therapy,  selectivity  of  inhibitors  for  a  specific  MMP  is  dramatically 
important, so much so that the lack of selectivity is believed to have been the main reason for 
failures of clinical trials in the past. Often, the failure of clinical trials, due to the severity of the 
side‐effects,  was  related  to  the  chronic  adverse  effects  of  nonselective  inhibitors  (i.e. 
musculoskeletal syndrome and tendinitis).[27] On the other hand, for the molecules proposed 
here, selectivity  is not an  issue as chronic use  is not required. Indeed,  ideal probes to detect 
overexpression of MMPs must not be selective inhibitors vs. a specific MMP, but they should 
instead selectively recognize MMPs among other proteins. These new biotinylated molecules 
designed  to  bind  to MMPs  and  to be  recognized by  avidin might  therefore be  successfully 
used in the in vitro collection/purification of MMPs, in the visualization of pathological tissues 
where MMPs  are  overexpressed,  and  to  evaluate  the  aggressiveness  of  the  pathology  by 
monitoring, e.g.,  radioactivity. Moreover,  it might be possible  to  test  in vivo  the efficacy of 
clinical treatments against a specific disease by  just monitoring the  level of MMPs produced 
during  the  therapy.  In  addition,  such molecules  can  be  easily  employed  for  collecting  and 
purifying MMPs from biological samples.  

































  As  zinc binding  groups  (ZBG),  the  carboxylic  acid was  selected despite  its  relatively 
weak affinity for the metal ion.[28‐30] In this case the choice of a carboxylic acid to replace the 
most  commonly  used  hydroxamic  acid  warrants  higher  stability  of  the  inhibitor  under 
physiological conditions[31] and provides better bioavailability.[32] 
  In all MMPs,  the  flexibility of  the protein  loops  forming  the active  site makes  these 
enzymes  able  to modify  the  shape  of  the  catalytic  pocket  to  accommodate  ligands  with 
different structures.[33‐35]  In particular, analyzing  the structures available on  the protein data 
bank,  it  is apparent that the volume of the S1 cavity can be changed to host  ligands bearing 
lipophilic groups of different size. However, in MMP‐1 and MMP‐7 the S1′ cavity is narrow as 







the affinity  in  the  low‐micromolar  range due  to  the  relatively  slim  size of  the S1′ pocket.[36] 
Although still good, 2 is a weaker MMP inhibitor with micromolar values of Ki for all the MMPs 
tested. 


















  Analysis of  the crystal  structures  revealed  that  the  inhibitors  share a  similar binding 




scaffold  2,  as  observed  in  the  enzymatic  assays.  Indeed,  in  the MMP‐12‐1  complex,  larger 
hydrophobic  interactions  result  from  the  larger  surface‐to‐surface  contact  area  due  to  the 
presence of the biphenyl moiety. More  important for the biotin tag  inhibitor design was the 




scaffold  2,  as  observed  in  the  enzymatic  assays.  Indeed,  in  the MMP‐12‐1  complex,  larger 
hydrophobic  interactions  result  from  the  larger  surface‐to‐surface  contact  area  due  to  the 
presence of the biphenyl moiety. More  important for the biotin tag  inhibitor design was the 
solvent  exposure  of  the  sulfonamide  nitrogen  revealed  by  the  crystal  structures  for  both 
ligands. These structural data address the question related to the identification of the position 
where the tag can be inserted without spoiling the binding affinity. 









bioavailability, stability, and solubility of  the whole molecule.  In particular, a  too‐long  linker 
can increase the susceptibility of the probe to be split by enzymes such as the biotinidase that 














































  The synthetical approach  that we had undertaken started  from biotin,  that was  first 
reacted under known procedures[38] with  the N‐Boc‐1,6‐diaminohexane 5  to give  the amido 
derivative 6 which, after quantitative removal of tert‐butyloxy carbonyl protecting group, gave 
the trifluoroacetylammonium salt 7. Compound 7 was treated with the bromosulfonamide 8 
in  the  presence  of  cesium  hydroxide,  in  dimethylformamide  as  solvent,  to  give  the 





































































































































































































when  the  resonance  assignment  is  available.[39]  The  complete  assignment  of  the  catalytic 
domain of MMP‐12 complexed with  the weak  inhibitor acetohydroxamic acid  is available  in 
our laboratory. Increasing amounts of 1 and 4 were added to 200 μM solutions of the protein 
up  to  an  equimolar  concentration. Although  several NH  signals were  shifted by  adding  the 
inhibitors, as many as 134 and 129  cross‐peaks belonging  to protein adducts with 1 and 4, 
respectively, were easily reassigned.  
  The  intensity  of  signals  belonging  to  NH  groups  perturbed  by  the  addition  of  the 
ligands decreased linearly, while new cross‐peaks corresponding to the BTI‐bound form of the 









Figure  13.  15N‐1H  HSQC  spectra  of  catalytic  domain  of MMP‐12  (red)  an MMP‐12  +  BTI  4 
(equimolar concentration) (blue).  
 
  The binding mode of  ligands  1  and  4,  respectively, was  analyzed  and  compared by 





In addition, a hypothetical binding mode with  the biotinylated  tail of BTI 4  fitting  in  the S1′ 
cavity  can be  completely  excluded by  the  chemical  shift perturbations on  the  15N‐1H HSQC 
spectra that are similar for 1 and 4 as well as by the Ki values of the BTI 10, which, although 
biotinylated,  showed  a  low  affinity  for  the  enzyme.  Likely,  extra  interactions  related  to  a 


















bifunctional  ligand  to  play  its  role,  only  the  ability  of  the  latter  to  bind MMP  and  avidin 
simultaneously could prove its real efficacy as effective BTI. 
  Two  different  approaches  based  on  NMR  spectroscopy  and  on  surface  plasmon 










complex.  Since multiple  binding  for  each  avidin molecule may  occur,  even  larger  protein 
complexes  are  expected  in  solution.  As  shown  in  Figure  15  (panel  D),  the  addition  of  an 











Figure 15. 15N‐1H HSQC spectrum of MMP‐12 catalytic domain  in the absence  (A) and  in the 






a  solution  containing 200 μM of NNGH‐inhibited‐MMP‐12  catalytic domain:  in  this  case, no 
changes were detected in the HSQC spectra. Therefore, we can reasonably conclude that the 
strong protein‐protein interaction, monitored by the 15N‐1H HSQC experiments, is mediated by 
the  BTI  4 which  is  able  to  bind MMP‐12  and  avidin  and  to  prevent,  at  the  same  time,  an 
extensive reciprocal reorientation of the complex subunits. Although NMR data allowed us to 
ascertain  that  4  does  bind  both  avidin  and  MMP‐12  simultaneously,  the  micromolar 
concentrations  used  for  these  experiments  do  not  provide  information  on  how  this 
simultaneous  interaction  may  affect  the  nanomolar  affinity  of  the  inhibitor  to  MMP‐12. 
Indeed, possible steric effects related to the presence of the hemopexin domain need to be 
evaluated  to understand  the  real binding  capability of  the probe  toward  functionally active 
enzymes.[42]  In  this  respect,  the  availability  of  the  active  full‐length MMP‐12  allowed  us  to 











  Surface plasmon resonance (SPR)  is widely applied to  investigate protein‐protein and 
protein‐ligand interactions.  Information on affinity constant, on binding kinetics, as well as on 
binding  enthalpy  can  be  quickly  obtained  by  using  small  amounts  of  protein  samples.  In 


























  The  employment  of  bifuctional  ligand  BTI  4  for  the  selective  collection  of  matrix 
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defined as  “a disorder of  the  tear  film due  to  tear deficiency or excessive evaporation  that 












watery  layer,  the  tear  film evaporates much  faster,  leaving dry  areas on  the  cornea. Many 
other factors, such as hot, dry or windy climates, high altitudes, air‐conditioning and cigarette 
smoke also cause dry eyes.  Many people also find their eyes become  irritated when reading 














The  precorneal  tear  film  consists  of  three  separate  layers: mucus, water,  and  oil.  Imaging 













very  dilute  saltwater  solution.  The  lacrimal  glands  under  the  upper  lids  and  the 






eye moist and comfortable, as well as  to help  flush out any dust, debris, or  foreign 
objects that may get into the eye. Defects of the aqueous layer are the most common 
cause of dry eye syndrome.  
• The most  superficial  layer  is a very  thin  layer of  lipids  (fats or oils). These  lipids are 
produced by the meibomian glands and the glands of Zeis (oil glands  in the eyelids). 













  Symptoms  seem  to  worsen  in  dry  climates,  in  windy  conditions,  with  higher 
temperatures, with  lower humidity, with prolonged use of your eyes  (for example,  reading, 
watching TV), and toward the end of the day. Sometimes a symptom of DES may actually be 
















factors and blinking may be another  contributing  factor because DES  is most  severe  in  the 
exposure zone that  is subjected to these stresses. If DES represents a chronic wound‐healing 
response,  then  it may be perpetuated,  in part, by  reduced  levels of  lacrimal gland‐secreted 
growth factors in the tear fluid. 
  Inflammation may  represent another  important  causative  factor  for DES. Decreased 
aqueous  tear  production  and  tear  clearance  leads  to  chronic  inflammation  of  the  ocular 
surface,  that  it  is  responsible  in  part  of  the  ocular  surface  epithelial  disease  and  irritation 
symptoms.  Increased  levels  of  inflammatory  cytokines  (as  IL‐1β  and  TNF‐α)  and 






importance  in  cleaving  epithelial  basement  membrane  components  and  tight  junction 
proteins  (such  as  ZO‐1  and  occludin)  that  maintain  corneal  epithelial  barrier  function.[9] 
Expression of MMP‐9 by the ocular surface epithelia in normal healthy eyes is low. 
Increased  production  of MMP‐9  by  the  corneal  epithelium  has  been  found  in  the  eyes  of 
individuals  with  sterile  corneal  ulceration:  moreover  increased  MMP‐9  activity  has  been 
associated  with  disruption  of  corneal  epithelial  barrier  function  and  corneal  surface 
irregularity  in  an  experimental murine model  of  dry  eye. MMP‐9  knockout mice  showed 




  Very  interesting  results  had  been  obtained  with  the  use  of  the  doxycycline  (a 
tetracycline antibiotic)  for DES. This  compound  is  in  fact well  recognized  for  its  therapeutic 














but  some of  these products are watery and alleviate  the  symptoms  temporarily; others are 
thicker and adhere to the eye longer. Preservative‐free tears are recommended because they 
are  the most  soothing  and  have  fewer  additives  that  could  potentially  irritate. In  fact  the 
frequent use of artificial tear solutions that are preserved with benzalkonium chloride may be 






















  To accomplish  that we decided  to use dendrimers. Dendrimers are macromolecular 








  In  ocular  drug  delivery  dendrimers  had  shown  several  potential  advantages.  Easily 
administered  as  eye  drops  with  a  good  patient  compliance,  they  had  demonstrated  a 
prolonged  residence  time at  the ocular  surface after  instillation and  they  could protect  the 
drug  loaded  against metabolic  enzymes. Moreover dendrimers  can be  tailored or modified 
into biocompatible compounds with low cytotoxicity. 
  Dendrimers are  classified and designed according  to  the  surface  terminating groups 
quality  (for example aminic,  carboxylic and hydroxylic groups) and quantity:  the number of 







  Polyamidoamine  (PAMAM)  dendrimers  are  the most  common  class  of  dendrimers 
suitable for many materials science and biotechnology applications. They presents a very high 














  Most common PAMAM dendrimers consist of alkyl‐diamine  core and  tertiary amine 







primary  amine  surface  groups.  The  surfaces  of  these  dendrimers  are  cationic  and  can  be 








  Following  this  strategy,  we  projected  the  synthesis  of  an  high‐reactive,  key 





  First  of  all,  the  sulfonamide  of  D‐serine  methyester  13  was  transformed,  under 
standard  conditions,  into  the  corresponding  tertbutyldimethylsilyl  ether  14,  then  it  was 
reacted with  the  first  part  of  the  linker  under Mitsunobu  condition  to  give  compound  15. 
Acidic removal of silylether protecting group afforded compound 16: this compound had been 




























































  After  the  achievement  of  17  we  had  to  find  a  conjugation method  to  effect  the 
covalent  linkage  of  our  inhibitor  to  the  PAMAM  dendrimer. We  had  to  chose  a  coupling 
reaction  that would  ideally proceed  in near quantitative yield. To achieve  this objective we 








































































































































































of  our  inhibitor with MMPs, we  synthesized  22  as  reference  compound,  starting  from  15. 
These compound had been deprotected  through hydrogenation ad  reprotected as acetyl  to 
mimic  an  amidic  bond  to  give  compound  23.  Acidic  removal  (CH3COOH/H2O  80:20)  of 
















































































  As we can notice  from  the data of compound 22,  the  insertion of  the  linker on  the 
sulfonamidic nitrogen of 12 gave a little increase in the affinity for MMP‐1 and ‐7 and a little 














































Compound  MMP‐1  MMP‐2  MMP‐7  MMP‐9  MMP‐12  MMP‐13 
25  286 nM  32.0 nM  7.40 µM  18.0 nM  45.0 nM  115 nM 
   
  As we had hypnotized, in this case the affinity vs. all the MMPs greatly increased with 
respect  to 21 dendron; probably, a  longer  linker was more  suitable  for  the  interaction with 
MMPs.  In particular,  the affinity vs. MMP‐1,  ‐2,  ‐9 and  ‐13,  that are directly  involved  in  the 
pathogenesis of the dry eye syndrome, was in the low nanomolar range. 

































































  Compound  29  had  been  coupled  with  PAMAM‐2  to  give  compound  30,  that  was 
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  Matrilysin  (MMP‐7)  is a member of the MMP gene family and, after being activated, 
has a broad proteolytic activity against a variety of extracellular matrix substrates,  including 
collagens,  proteoglycans,  elastin,  laminin,  fibronectin,  and  casein.  Compared  with  other 
MMPs, matrilysin  is  distinguished  by  its  low molecular mass  (28  kDa)  and  its  lack  of  a  C‐
terminal domain;  this C‐terminal domain  is  found  to be present  in almost all of  the MMPs 









  MMP‐7  has  been  specifically  implicated  as  an  important  facilitator  of  tissue 
remodeling due  to  its  ability  to  cleave  a  variety of  known  substrates,  including many  ECM 





and  tumor  cell  invasion using  in  vitro model  systems.    For  tumor  systems  in which MMP‐7 






earliest  stages. Small, benign  “precancerous”  lesions,  for example, exhibit MMP‐7  secretion 
well  before  these  lesions  would  be  clinically  detectable.  Furthermore,  analysis  of MMP‐7 
expression  in  human  neoplasia  revealed  that  enzyme mRNA  appeared  in  the  surrounding 
normal tissue in only a few isolated cases, suggesting highly specific enzyme expression in the 
immediate tumor vicinity. The  larger and more progressed these tumors become, the higher 
the MMP‐7  levels  tend  to  be. Moreover,  intestinal  tumorigenesis    is  suppressed  in mice 
lacking matrilysin.[3] In addition, approximately 80% of spontaneous tumors analyzed express 
matrilysin  .  Taken  together,  these  findings  suggest  that  inhibition  of matrilysin  activity  in 
human colorectal cancers may provide a protective effect.  
  Furthermore,  MMP‐7  has  proven  to  have  diagnostic  and  prognostic  value,  as 




potential  of  colon  cancer  cells,  and  that  an  antisense  oligonucleotide  against  MMP‐7 
suppresses  liver metastasis.  These  results    suggest  a  significant  role  for MMP‐7  in  tumor 
invasion and metastasis even at late stages of colon cancer progression.[4] 









recognized  by MMP‐7:  only  after  the  cleavage  operated  by matrilysin  in  a  specific  region 
(where  the MMP‐7 was overexpressed) our pro‐inhibitor should be opened and only  in  this 




























  We  firstly  synthesized  the  sulphonamidic  inhibitor  that  contained  the 
aminoacid serine (that it is the first aminoacid before the cleavage operated by MMP‐












aminic  group),  and  after  the  achievement  of  derivate  34  starting  from  the  L‐
serinemethylester  hydrochloride  we  added  the  other  two  aminoacids  of  the 




































  The  synthesis  of  compound  35  was  optimized  and  afforded  the  desired 
compound  in a very good yield  (35% on 11 steps). We started  from L‐serine methyl 
ester, that was firstly selectively benzylated on the aminic group (compound 36)[6] and 
then mesylated on the oxydrilic group to obtain the  intermediate 37. The reaction of 
compound  37  with  sodium  azide  was  performed  under  optimized  conditions 
(CH3CN/DMF   4:1, 60 °C); a single product was  isolated  in 75% yield whose structure 
was determined to be (R)‐methyl α‐azido‐β‐N,N‐dibenzyl propionate (38). Methyl N,N‐
dibenzyl‐β‐azido alanate (39) resulting from the formal direct nucleophilic substitution 









































  Staudinger  reduction of  the azide 38 gave  the diamine 40  in 94%  yield. This 
compound  was  been  reacted  with  p‐metoxybenzensulfonyl  chloride  to  obtain 


























































































































































be  revealed  and we will  have  the  active  form  of  the  inhibitor.  After  the  coupling 














































different  points  (shown  in  red)  to  give  two  desired monomers,  that  was  the  real 
inhibitors.   On compound 47 we performed kinetic  studies by  fluorimetric assays  to 
understand if MMP‐7 should be able to cleave the cycle as we have hypothesized. The 
dimer  47  was  incubated  with MMP‐7  for  10’,  30’,  1h,  12h,  24h  and  the  Ki  were 
measured. Since Ki didn’t change evidently during the investigation period, these data 
suggested us  that probably  the dimer was not  recognized by  the protein and  it was 
not cleaved by MMP‐7. 
  On the other hand, the interaction between 35 and 33 vs. different MMPs had 




Compound  MMP‐1  MMP‐7 MMP‐8 MMP‐12
33  101 uM  146 uM 3.90 uM 













MMP‐7, we  also  synthesized  another  compound  presenting  a  different  aminoacidic 
sequence  (VPQS‐LTMG).  The  synthesis  was made  as  describe  above  starting  from 














































  Lateral  chain  of  the  aminoacid  threonine  of  compound  49 was  deprotected 




























































 Compound  MMP‐1  MMP‐7  MMP‐12 
51  21.1 uM   38.0 uM  1.21 uM 





probably  the  substitution  of  a  lipophilic  and  little  aminoacid  as  alanine  with  a 
threonine was not efficient for the interaction with the protein. Moreover the Ki does 
not change markedly  in the case of MMP‐1 and MMP‐12, while for MMP‐7 it is more 
than one order of magnitude:  this was probably due  to a  specific  interaction of  the 
aminoacidic chain of compound 35 with the protein. 
  Considering that compound 35 presented a good affinity for MMP‐7 even  if  it 





























































  In  this  case  we  needed  a  compound  as  reference  to  understand  if  the 




















 Compound   MMP‐1  MMP‐7 MMP‐12
52  135 nM   562 nM  10.5 nM 











  What  is more  the  comparison  between  Ki  values  of  compound  52  and  34 





























  To  date,  poor  oral  bioavailability  of MMPIs  remains  the most  frequent  cause  for 
failure  in  clinical  drug  development.  Indeed,  up  to  now,  only  very  few  of  the  plethora  of 
potentially  useful  MMPIs  reported[1‐3]  are  water  soluble.[4‐6]  Indeed,  solubility  in  water  is 
required for maintaining high drug  levels  in plasma, which  is essential for treatments relying 
on oral administration. Doses of drug higher  than  those based on  intrinsic efficacy must be 
administered because of  limited bioavailability. High doses,  in  turn, exacerbate  the adverse 
effects of modest selectivity by causing indiscriminate inhibition of other zinc endopeptidases. 
  Furthermore,  MMP‐related  pathologies  are  usually  chronic  and  any  plausible 
pharmacological  scheme  would  require  long  term  treatment,  during  which  time  lipophilic 
drugs tend to accumulate  in  tissues and thereby enhance side effects. High  lipophilicity also 
increases  binding  affinity  to  human  serum  albumin  (HSA).  Strong  binding  to  HSA  has  an 
adverse  effect  on  bioavailability  by  increasing  the  half‐life  in  vivo  and  preventing  the  drug 
from reaching the target site.   To date, poor oral bioavailability of MMPIs remains the most 
frequent  cause  for  failure  in  clinical drug development. Consequently, alternative  routes of 
administration[7] as well as new hydrophilic inhibitors were explored. 
  However,  high  affinity  for  MMPs  is  often  achieved  by  introducing  lipophilic 




























most  prominent  representatives  of  a  family  of  inhibitors  possessing  nanomolar  affinity  for 
several MMPs.[9] The NNGH  family of  inhibitors suffers  from  the major drawbacks discussed 
before,  and  is  therefore  inadequate  for  most  applications.  The  published  X‐ray 
crystallographic structure of the NNGH–MMP‐12 complex[10] allowed us to ascertain that the 
interaction  of  the  inhibitor  with  the  active  site  of  the  enzyme  involves  binding  of  the 
hydroxamate moiety  to  the  catalytic  Zn  ion  and  binding  of  the  aromatic  group  to  the  S1’ 
subsite., while  the  isopropyl group on  the sulfonamide nitrogen atom points away  from  the 
shallow S2’ pocket and does not directly participate in binding.  
  In an effort to overcome the limitations of NNGH, this structural information was used 
to  prepare  a  new  family  of  MMPI,  whereby  the  isopropyl  group  was  replaced  with  a 
hydrophilic moiety.  The  leading  concept  in  designing  of  this  compounds was  to  replace  a 
portion of  the molecule not directly  involved  in binding with a water‐soluble  residue  in  the 
hope  that  its  inhibiting  properties would  not  be  affected.  It must  be  emphasized  that  the 
addition a hydrophilic residue to this type of inhibitors is unprecedented in the NNGH family.  
  The extensive NMR and X‐ray  studies  to elucidate  the binding  interactions between 
functional  groups  in  the  inhibitors  and  their  corresponding  subsites  in  the  enzymes[1]  have 












































  Glucoside  55  is  a  new  carbohydrate‐based  inhibitor,  unprecedented  in  the  NNGH 
family, that displays nanomolar affinity toward several MMPs. Compound 55 is water soluble 
(>  30 mM)  and  does  not  appreciably  interact with HSA.  A  distinct  advantage  of  55  is  the 
modular  adaptivity  of  the  design  to  the  desired  hydrophilicity, which  can  be  appropriately 
tuned to specific applications by simply varying the number and the nature of substituents on 
the  carbohydrate  residue.  This  type  of  glycosilated  compounds  can  be  used  to  target  the 
inhibitor versus particular tissues, decreasing in prospective the side effects and increasing the 
efficacy. 
  This  inhibitors was  synthesized  through  a  general  synthetic  pathway.  Starting  from 
compound 56,[11] we synthesized a group of carbohydrate‐based inhibitors; here we reported 
in  particular  the  synthesis  of  compound  57,  that  present  as  saccharidic  mojety  an  N‐Ac 
glucosamine. The  synthetic patway, which produces  the glycosidic  β  isomer exclusively, has 






























































































  The  affinity  properties  of  57  and  59  derivatives  toward  the  selected MMPs  were 
evaluated  by  fluorimetric  assay, while  the  assays  on  compound  58  are  in  progress.  The  Ki 
values are reported in Table 10, in comparison to compound 55.  
Table 10. Inhibition Constants (Ki) of the 55, 57 and 59 toward the considered MMPs. 





















all  the  compounds, direct evidence of  the  lack of  significant participation  in binding of  the 
carbohydrate moiety that was demonstrated from the X‐ray crystal structure of the MMP‐12–
55  complex  (Figure  31).  The  structure  is  strictly  analogous  to  that  of  the  complex  with 




in  the crystal. The  lack of  strong  interactions with  the protein  residues causes an  increased 
mobility of the glucose moiety, reflected in the lower definition of some of the corresponding 



















we additionally  reported  the synthesis and binding assessment of a  family of  low molecular 
weight, efficiently prepared, water‐soluble inhibitors. Low nanomolar affinities were assessed 
for  these  new  inhibitors  to  some  relevant  MMPs  such  as:  MMP‐12,  implicated  in  the 




were  reacted  with  solfenylchloride  in  the  presence  of  triethylamine  and 



















a) Et3N, DMAP, CH2Cl2, rt, overnight, 90-97 %
60 R = H
61 R = CH2OH
62 R = CH(CH3)OH
63 R = H
13 R = CH2OH





The  sulfonamide  of  glycine  methylester  63  was  reacted  with  ethylene  oxide  and 
methyliodide[11]  to  afford  compound  56  which  was  directly  transformed  into  the 
corresponding  hydroxamic  acid  65  by  reaction  with  hydroxylamine  hydrochloride  and 
potassium hydroxide,  in methanol as  solvent  (Scheme 23). Compound   63 was also  reacted 
with  enantiopure  glycerine  dimethylacetal  66  under  Mitzunobu  conditions,  to  give 


















































































a)[11],  64%;  b)  NH2OH











































located outside  the protein does not appear  to contribute  to binding, while  the hydroxamic 
acid  is oriented toward the catalytic zinc ion.  
For  the  synthesis of a more  soluble analogues of  compound 70,  the  sulfonamide of 



























































Acidic  removal  of  silylether  and  acetal  protecting  groups  afforded  a mixture  of  tri‐
hydroxyl derivative 72 and  lactone 73 which was  treated with hydroxylamine hydrochloride 
and potassium hydroxide to form the expected hydroxamic acid 74 in 50% yield (Scheme 24). 
In  parallel  to  this, we  synthesized  the  corresponding  biphenyl  derivative  of  compound  70, 
starting  from  60  and  biphenylsolfenylchloride,  to  give  the  sulfonamidic  derivative  75.This 
compound was  reacted  under Mitsunobu  conditions with  66  to  give  compound  76.  Acidic 
removal  (CH3COOH/H2O  80:20) of  acetal protecting  group on  76  afforded  a mixture of  the 



















































































































was  replaced  by  para‐fluorobenzyl‐  and  biphenyl‐moieties.  Therefore,  the  para‐
fluorosolfonamide  of  glycine  methyester  81  and  the  biphenylsolfenamide  of  glycine 


















83 R = Ac




























82 R = Ac





















































































































on  the  sulfonamidic  nitrogen  with  an  hydrophilic  moiety  not  only  doesn’t  invalidate  the 
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  Most  biological  processes  are  controlled  by  molecular  interactions  that  involve 
peptides  and  proteins.[1]  Drug  discovery  processes  often  start  by  identifying  peptides  that 





like molecules  has  often  been  approached  systematically  by  identifying  the  key  elements 
responsible  for  activity  in  terms  of  essential  amino  acid  residues  and  their  presentation  in 




1980  onwards.  Approaches  have  varied  greatly,  from  peptide‐like  templates,  such  as 





create  molecular  diversity  in  a  modular,  systematic  and  tailored  way  (structurally  and 
functionally) is unique to carbohydrates. It is self evident that such approaches are not limited 
to mimicking peptides. Molecular diversity can be tailored, at least in principle, to any target. 
We  have  applied  this  concept  in  the  development  of  a  α‐O‐linked  glycohomoglutamate,[2] 
easily  obtained  as  distereomerically  pure  compound  by  chemo‐,  regio‐  and  stereoselective 































our  scaffold  retains  the  4C1  chair  conformation,
[4]  maintaining  biomimetic  properties  as 
documented by combined molecular modeling and NMR  spectroscopic analyses.  In  fact  the 
sugar part of our molecules retains bioactivity for the different lectins investigated. For these 
reasons, our scaffold can be considered a promising candidates for further exploitation of this 
type  of  derivatives  to  give  O‐glycans  for  lectin  blocking  and  vaccination.  Concerning  this 
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E-mail address: cristina.nativi@unifit.it (C. Nativi).Cyclic peptidomimetics are attracting structures to obtain a distinct, bioactive conformation. Even more
attractive are sugar-containing cyclic peptidomimetics which present turn structures induced by the
pyranose ring when incorporated in cyclic peptides. The use of a new and versatile saccharidic scaffold
to achieve sugar-based peptidomimetics is here reported together with the successful synthesis of diaste-
reomerically pure cyclic SAA peptidomimetics 15 and 16.
 2009 Elsevier Ltd. All rights reserved.Low bioavailability, poor stability towards peptidases and rapid
excretion displayed by a large number of peptides of therapeutic
and biological interest, prompted an intensive search for pepti-
domimetics.1–3 As a matter of fact, peptidomimetics molecules,
are expected to have the same therapeutic effects as their peptide
counterparts, with the added advantages of metabolic stability and
bioavailability.
A possible approach of such peptidomimetics is to replace the
peptide, or part of the peptide, by a scaffold that distributes in
the space the epitopes. Ideally, an attractive scaffold should easily
be available as chiral, enantiomerically pure, building block. It
should be highly functionalized to introduce various side chains
and its flexibility or rigidity could be modulated. Therefore, the
use of sugars as scaffolds in mimetic synthesis is a strategy that
has been widely studied and which still draws attention.4–6
Sugar derivatives can be incorporated in the peptide backbone
or in the side chains; modification of peptide skeleton by introduc-
ing carbohydrate derivatives is documented leading to a real
improvement of the properties of the peptides. Moreover, because
of the presence of pyranose ring, sugar aminoacids (SAAs) have
been found to introduce turn structures when incorporated in lin-
ear or cyclic peptides.5ll rights reserved.Cyclization of peptides affords structure of special interest to ob-
tain a distinct, bioactive conformation, and several SAAs have been
used as building blocks for peptide scaffolds and conformational
restrained peptido-mimetics.2,7 Indeed, this approach has been suc-
cessfully evaluated for biologically active, cyclic RGD peptides3 or
cyclic peptides with the b-turn motif of somatostatin, containing
tetrapeptide Phe-D-Trp-Lys-Thr.2,8
Consequently, efficient syntheses and availability of suitable
saccharidic scaffolds allowing the systematic modification of the
amino acids and the carbohydrate residues, as well as the size of
the macrocycle, remain a challenging and attracting target to fully
exploit the potential of such hybride structure, in the search of new
active compounds.
We report herein the use of the a-O-linked glycohomoglutamate
1, (Scheme 1), easily obtained as distereomerically pure compound
by chemo-, regio- and stereoselective cycloaddition between glucal
2 and aspartic acid derivative 3,9 as versatile, multifunctionalized
scaffold in the synthesis of cyclic SAA-peptidomimetics 15 and
16 (Scheme 2).
Scaffold 1, characterized by two orthogonally protected carbox-
yls, a protected a-amino function and a selectively functionalized
monosaccharidic unit, was successfully employed to obtain the
monosilyl derivative 4 which, in turn, was oxidized with TEMPO/
BAIB to give the glucuronic derivative 5 (see Scheme 1) in 54%
yield. No sulfoxide derivative 6 was observed under these reaction























































Scheme 1. Synthesis of scaffold 5 and structure of cyclo SAA peptidomimetics 15 and 16.
3842 M. Altamura et al. / Bioorg. Med. Chem. Lett. 19 (2009) 3841–3844between 5 and 7 as well as between 5 and 8 were performed using
standard conditions (see Supplementary data) affording respec-
tively compounds 9 and 10 (Scheme 2). Peptidic chains 7 and 8
as well as SAA derivatives 9 and 10 have been obtained relying
on standard solid-phase strategy, using 2-chlorotrityl resin. Re-
moval of the resin, gave linear glycopeptides 11 (62%, over 10
steps) and 12 (25%, over 11 steps) which were treated with triflu-
oroacetic acid to take off the Boc protecting group quantitatively
affording derivatives 13 and 14, as trifluoroacetic salts. Intramolec-
ular condensation of the latter, and suitable deprotection, gave the
cyclo glycopeptides: cyclo(SAA5-Ala-Phe-Phe-Phe-Ala) 15, and cy-
clo(SAA5-Glu-Ile-Leu-Asp-Val) 16, (see Supplementary data) which
were prepared to be tested as tachykinin NK2 receptor ligand and
integrin (a4b1) inhibitor respectively (Scheme 2).
In a previous paper11 we have shown how insertion of aromatic
groups on a suitable sugar derived scaffold can mimic the structure
of highly active tachykinin NK2 antagonists such as the small
monocyclic pseudopeptide 1712 (Fig. 1).
Indeed, some of the compounds we obtained showed binding
affinities at the human tachykinin NK2 receptor at submicromolar
concentrations, while molecular dynamics calculations indicated
that the structures of 17 and that of one of the best sugar derived
compounds were quite well superimposable. As tachykinin NK2
antagonists continue to raise interest as potential new drugs for
the therapy of gastrointestinal and CNS diseases,13 we turned our
attention to the synthesis of compounds in which small peptide se-
quences, containing aromatic aminoacids (Phe) and alanine resi-
dues as chiral spacers, are linked to the sugar derived rigid














Figure 1. Structure of compound 17.space regions. We thus synthesized compound 15 which showed
some, although limited, activity in the binding assay at the human
tachykinin NK2 receptor. Affinity of compound 15 at the human
NK2 receptor was determined in binding experiments by using
membranes of Chinese Hamster Ovary (CHO) cells stably transfec-
ted with the human NK2 receptor.14 The compound was tested for
its ability to displace the radioligand [125I]-neurokinin A (0.15 nM)
after 30 min incubation at room temperature, resulting in 25%
inhibition of the radioligand binding at 10 lM concentration.
Capitalizing on this encouraging result, further work is ongoing
in order to increase the biological activity through the modulation
of the peptide sequence assisted by molecular dynamics
calculations.
It is known that a requisite for a good recognition by NK2 recep-
tors is the presence of two close aromatic rings in the axial position
about the backbone ring.15 We performed a preliminary modeling
study of compound 15 to locate its allowed conformations;16 the
molecule showed a high degree of conformational flexibility and
several populated geometries. Among them, two significant con-
formations show two of the three phenyl rings oriented in the
same region of the space, though they do not belong to adjacent
aminoacidic residues as in 17. These conformations, reported in
Figure 2, are stabilized by a b-turn motif and support the potential
interest in such cyclic glycopeptidic structures.
Integrins are a family ofmembrane-spanning adhesion receptors
composedof non- covalently linkeda andb subunitswhich combine
togive awideamountofheterodimers. In recentyears antagonists of
very late antigen-4 (VLA4, also known as integrina4b1) have shown


































































































R' = H2+CF3COO- ; 13
R' = Boc; 11
TFA (1% in CH2Cl2)
62% (over 10 steps)
TFA (1% in CH2Cl2)
25% (over 11 steps)
R' = H2+CF3COO-; 14



















































































R = H; R' = Bn; 20
R = H; R' = OH; 16 (40%, over two steps)
H2/ Pd(OH)2
MeOH
R = TIPS; R' = Bn; 19
R = H; 15 (50%)




Scheme 2. Synthesis of open-chain SAA peptides 13 and 14.
M. Altamura et al. / Bioorg. Med. Chem. Lett. 19 (2009) 3841–3844 3843nizes polypeptide domains containing theGlu-Ile-Leu-Asp-Val ami-
noacid sequencewhose specificity and efficacy is determined by the
contest (flanking residues, conformational presentation, etc.). A
number of peptidomimetics have been proposed as anti-VLA4
agents and in this contest the cyclo SAA peptidomimetic 16was pre-
pared and tested for inhibitory activity against a4b1 integrin by
assessing ability to inhibit the adhesion of U937 and Jurkat cells to
a VCAM-1 coated surface20 demonstrating a lack of inhibition of
these processes up to a concentration of 100 lM.
In summary, the monosaccharidic scaffold 5, efficiently ob-
tained as diastereomerically pure compound, was successfully
used to synthesize cyclic SAA peptidomimetics. As suggested bymolecular calculations, a pentapeptidic sequence should well fit
to form macrocyclic structures, therefore biologically engaging
compounds 15 and 16 were prepared as single diastereoisomers.
Cyclo(SAA5-Ala-Phe-Phe-Phe-Ala) 15 was tested as tachykinin
NK2 ligand, showing some, although limited, activity which can
likely be rationalized on the basis of a correct orientation of its
phenyl groups. Cyclo(SAA5-Glu-Ile-Leu-Asp-Val) 16, however, did
not exhibit activity against a4b1 integrin. Relying on the versatility
and potentials of the scaffold 5 we propose herein, assisted by
molecular modeling studies, further work is ongoing to prepare
an array of cyclic SAA peptidomimetics containing proper peptidic
chains to interact with specific biological targets.21
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Introduction
Protein glycosylation, which rivals phosphorylation in its fre-
quency, imparts a series of distinct properties to a carrier
backbone. They range from changes in physicochemical pa-
rameters, such as solubility and protection from proteolytic
degradation, to adding versatile docking sites for the recep-
tors that read the sugar-encoded information.[1] A character-
istic of secretory or polarized epithelia, and also encoun-
tered in different cell-surface glycoproteins, is the presence
of mucin-type O-glycosylated positions linked to serine/
threonine residues via an a-N-d-acetylgalactos ACHTUNGTRENNUNGamine
(GalNAc) moiety that are often subject to intimate structur-
al control.[2] When clustered together and arranged in re-
peats, the resulting glycoproteins are referred to as mucins.
They can form a highly stable viscoelastic gel over epithelial
cell surfaces, thus providing a protective barrier against ex-
ternal agents. Equally importantly, their glycan part can me-
diate cell adhesion and attachment processes that initiate
bacterial infection or leukocyte infiltration into inflamed
tissue, here recruiting the sialomucins CD34 or GLYCAM-1
and PSGL-1 as ligands for the C-type lectins of the selectin
group.[3] Since these recognition processes with O-glycans
extend to other lectin classes, such as adhesion/growth-regu-
latory galectins and to clinically relevant events in the meta-
static cascade, it is a challenge to develop bioactive mimetics
that would also be useful as vaccines against mucin-based
tumor-associated antigens.[4] Towards this end, we directed
our efforts to the diastereoselective synthesis of mucin-like
scaffolds, which maintain the key structural features of such
natural glycoproteins and present suitable functional groups
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for the insertion of a saccharidic moiety and one or two pep-
tidic chains or a peptidic chain and a carrier, as required for
generating synthetic vaccines against tumor-associated gly-
copeptide antigens.[5] Since the synthesis of naturally occur-
ring glycopeptides is tedious, often ending up in diastereo-
meric mixtures, one focus in this area is glycopeptide mimet-
ics.[6] As an added advantage, the latter can have improved
stability against chemical and enzymatic hydrolysis and, de-
pending on the type of substitution, improved bioavailability
compared to natural materials.
In the course of the rational design of glycopeptidomimet-
ics, it is mandatory for these neoglyco derivatives to retain
bioactivity, that is, the capacity to serve as ligands for specif-
ic receptors. Thus, synthetic products need to be rigorously
controlled by respective assays, in our case tested against a
plant lectin with affinity to galactosides including the Thom-
sen–Friedenreich antigen, which is often present in mucins,
or its Galb1–3Gal derivative as a model.[7] Viscumin, also re-
ferred to as Viscum album agglutinin (VAA), is a potent
biohazard akin to ricin, whose toxicity can be neutralized by
suitable inhibitors competing with the cognate cell-surface
glycans.[8] This perspective has made the toxin a model for
drug design, for example, applying library approaches in
search of new binding partners.[9] In a more general context,
the strategy of combining preparative synthesis of glycopep-
tide mimetics with affinity testing will not only explore this
substrate class as potential source for new pharmaceuticals
but also enable us to gain insights into structural aspects of
the recognition process, which have relevance for under-
standing and exploiting lectin–carbohydrate interactions.[10]
Results and Discussion
Synthesis : The entirely diastereoselective synthesis of glyco-
peptide scaffolds that preserve the natural a-O-glycosyl link-
age is based on an efficient cycloaddition between galactal
1, as electron-rich dienophile, and homoglutamate 2, as elec-
tron-poor diene[11] (Scheme 1).
The attack of the heterodiene 2 exclusively on the bottom
(a) face of the dienophile 1 resulted in the a-O-glycosyl de-
rivative 3 as the single diastereomer, in a 70% yield. Treat-
ment of 3 with trifluoroacetic acid enabled removal of the
tert-butoxycarbonyl group without affecting the silylidene
protecting group on the galactose moiety, leading to the
amino derivative 4. Under basic conditions, compound 4 un-
derwent cyclization to give the tricyclic lactam 5 in a 65%
yield (calculated over two steps). Galactosyl amino acid 5 is
a versatile scaffold that presents an a-glycosyl linkage and
decorated with three hydroxyls and one carboxylic group.
Treatment of scaffold 5 with hydrogen fluoride/pyridine
(70%) in dichloromethane and methanol at room tempera-
ture facilitated the removal of the silylidene and benzyl
ester protecting groups to produce unprotected scaffold 7 as
a diastereometrically pure compound, in one step and in
87% (Scheme 2).
Under these reaction conditions, first the removal of silyli-
dene occurred, followed by nucleophilic cleavage of the
benzyl ester. In fact, if the deprotection reaction is stopped
after one hour instead of four, the benzyl derivative 6 was
isolated in 90% yield. Focusing our attention on the devel-
opment of a synthetically convenient compound for tests as
a bioactive ligand, with perspectives for application as a vac-
cine against a-Tn and a-TF antigens, we started with scaf-
fold 5 to prepare the glycopeptide mimetic 8, its sugar part
then extended to the disaccharide 9 (Scheme 3).
After selective removal of benzyl ester under standard
conditions (90%), scaffold 5 was transformed into derivative
10 (Scheme 4). It presents a free carboxylic residue that is
suitable for the introduction of a serine moiety. Indeed, the
serine methyl ester was treated with 10 in the presence of
O-(7-azabenzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium
hexafluorophosphate (HATU) and N-methylmorpholine
(NMM) at room temperature and in dimethylformamide as
solvent to give the glycopeptide mimetic 11 in 93% yield.
Removal of the silylidene protecting group, as reported
above, followed by deprotection of the serine carboxylic res-
idue, with lithium hydroxide/water, in tetrahydrofuran/water
Scheme 1. Synthesis of a-O-galactosyl scaffold 5. a) pyridine, CHCl3,
45 8C, 24 h, 70%;[11] b) CF3COOH, CH2Cl2, RT; c) triethylamine, CHCl3,
40 8C, 40 h, 65% (over two steps).
Scheme 2. Synthesis of deprotected scaffolds 6 and 7. a) HF/pyridine
(70%), CH2Cl2, 0 8C, 1 h, 90%; b) HF/pyridine (70%), CH2Cl2/MeOH,
RT, 4.5 h, 87%.
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as solvent at 0 8C (39%, calculated over two steps), afforded
the fully unprotected building block 8.
Glycosylation, under Schmidts conditions, of scaffold 5
with the glycosyl donor 12[12] then gave the disaccharide 13,
as single b-diastereoisomer in 75% yield (Scheme 5). De-
acetylation under standard conditions, in methanol as sol-
vent, resulted in the disaccharide 14 as a methyl ester
(60%). The latter was then treated with HF/pyridine and
lithium hydroxide to obtain the completely unprotected di-
ACHTUNGTRENNUNGsacACHTUNGTRENNUNGcharide 9 in 56% yield (calculated over two steps). This
product was further studied to evaluate its conformational
properties.
Conformational analysis in solution by NMR spectroscopy
and molecular modeling : Analysis of the vicinal proton–
proton coupling constants (Table 1) for the pyranose rings
of 7 and 8 indicates the exclusive presence of the 4C1 chair
conformation, as for natural galactosides.[13] Indeed, most of
the NMR parameters regarding the shape of the bicyclic
moieties of these compounds were very similar, thus indicat-
ing no influence from the presence of the Ser moiety in 8.
Results obtained from MM3*-based molecular mechanics
calculations[14] also support these observations, with the 4C1
chair form being more than 3 kJmol1 more stable than the
1S3 skew-boat conformation and much more stable than the
alternative 1C4 chair conformer. The major difference con-
cerns the orientation around the C5C6 torsion angle. For 7,
the observed JH5,H6a and JH5,H6b values (4.6 and 10.1 Hz) are
in agreement with a major conformation of this torsion, in
contrast to the equilibrium usually observed for galactoside
derivatives.[15] On the other hand, the observed intermediate
values (4.5 and 7.9 Hz) for 8 are accounted for by the ex-
pected gt:tg conformational distribution. For 8, the Jab and
Jab’ values are also on an intermediate level (4.0, 5.0 Hz);
this indicates the existence of an equilibrium around the
CaCb lateral chain. Molecular dynamics simulations (5 ns
with the MM3* force field) were performed (Figures 1 and 2
and Supporting Information). The results disclose that the
chair conformer is very stable, with basically no fluctuations.
Moreover, motion around the pseudoglycosidic F (H1’-C1’-
O-C2) and Y (C1’-O-C2-C3) angles is also rather restricted
for both molecules, with values centered around +808 and
1808. However, fluctuations take place around the region
containing the nitrogen atom, defined by torsions f1 and
f2, giving rise to two geometries (Figure 2).
The first conformer (A) is defined by f1 (defined as
C1-C2-C3-N4) +488 and f2 (defined as C2-C3-N4-C5)
358. The second one (B) is defined by f1, f2 angles
around 458 and +358, respectively (Figures 1 and 2). Com-
parison of the expected couplings with those experimentally
Scheme 3. Structure of a-Tn, a-TF, and scaffolds 8 and 9.
Scheme 4. Synthesis of scaffold 8. a) Pd(OH)2/C (20%), H2, EtOAc/
CH2Cl2, RT, 2 h, 90%; b) SerACHTUNGTRENNUNG(OMe), N,N-dimethylformamide, NMM,
HATU, RT, 2 h, 93%; c) HF/pyridine (70%), CH2Cl2, RT, 2 h; d) LiOH/
H2O (0.04m), THF/H2O, 0 8C, 1.5 h, 39% (over two steps).
Scheme 5. Synthesis of scaffold 9. a) CH2Cl2 at 30 8C then TMSOTf at RT, 2.5 h; Et3N (Ph 7), 75%; b) CH3ONa, CH3OH, 0 8C, 1 h, 60%; c) HF/Py
(70%), RT, 2h, d) LiOH, H2O (Ph 10), RT, 2 h then H3PO4 (Ph 7), 56% (over two steps).
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observed for the C2C3 fragment enabled us to deduce that
both conformers are present in solution to a significant
extent, with an approximate A/B ratio of 40:60 for 7 and
50:50 for 8. Overall, this slight 10% shift of the conforma-
tional equilibrium is almost negligible considering the DG
parameter. Calculation of the expected J values for the en-
semble deduced from the MD simulations enabled us to
quantitatively explain the experimental observations
(Table 1) and NOEs (Supporting Information).[16,17]
Next, the conformational behavior of the Galb1–3Gal an-
alogue 9 was investigated. In this case, a mixture of stereo-
isomers at the a-carbon of the amino acid was obtained.
Nonetheless, its presence does not preclude testing the bio-
activity, so a qualitative conformational analysis of both iso-
mers was performed. The coupling constant data (see
Table 2) revealed that both galactose residues adopt the
usual 4C1 chair geometry. The existence of a inter-residual
Gal H1’–Gal H3 NOE indicated the presence of a typical
exo-anomeric geometry[18] around the glycosidic linkage.
Chemical shift and coupling constant data, as deduced from
analysis of the 2D 1H NMR spectra, are given in Table 2.
With this information, molecular-mechanics calculations
were performed for both diastereomers, and the expected
coupling constants were compared to those experimentally
observed. Since the two Ha protons for both diastereomers
can be distinguished in the 1H NMR spectrum, the couplings
to the corresponding Hb could easily be measured. The
values range between 5.1 and 7.9 Hz (Table 2), thus indicat-
ing that a conformational equilibrium, similar to that de-
Table 1. Chemical shifts and coupling constants of compounds 7 and 8, measured in D2O (500 MHz, 298 K, phosphate buffer: 20 mm, pH 5.8). The theo-
retical values (Jtheor) were obtained by applying the generalized Karplus equation proposed by Altona to the geometries calculated by the MM3*-based
calculations. The gt conformer around the C5C6 torsion was employed.
Compound 7 Compound 8












H1’ 5.74 1’/2’ 3.0 2.6 2.6 5.80 2.9 1.4 1.5
H2’ 3.42 2’/3’ 11.3 11.4 11.4 3.48 11.3 10.9 10.9
H3’ 3.75 3’/4’ 3.1 2.8 2.8 3.77 2.7 2.2 2.3
H4’ 3.96 4’/5’ <1 0.8 0.8 4.02 <1 0.2 0.3
H5’ 4.12 5’/6’a 4.6 2.0 2.3 4.15 4.5 4.7 1.6
H6’a 3.70 5’/6’b 10.1 9.7 10.4 3.73 7.9 10.5 9.8
H6’b 3.65 3.72
H2a 2.87 2a/3 5.3 5.0 5.1 3.11 5.5 4.0 5.0
H2b 2.67 2b/3 7.7 11.0 1.8 2.82 6.5 11.3 1.7
H3 4.05 4.39
Hb,b Ser 3.89 a,b 5.0 1.0 10.7
Ha 4.43 a,b’ 4.0 2.4 4.5
HN 7.21 (H2O) 7.67 (H2O)
HN-Ser 8.22
Figure 1. A) The two major conformers of 7 (A and B) according to the
experimental NMR data and MM3*-based molecular mechanics and dy-
namics calculations. This orientation of the lactam defines the two ge ACHTUNGTRENNUNGom-
ACHTUNGTRENNUNGetries by the MD. B) Superimposition of the two major conformers of 8
according to the experimental NMR data and MM3*-based molecular
mechanics and dynamics calculations. This orientation of the lactam de-
fines the two geometries, which show rather different spatial orientations
of the Ser moiety. The additional mobility at the Ser moiety is not de-
fined here, although it is manifested in the NMR data.
Figure 2. Plot of the f1/f2 values sampled during the 5 ns MD simula-
tions performed for 8 with the MM3* force field and the GB/SA solvent
model. The data for 7 are basically identical.
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scribed above for 7 and 8, is also present. A view of the
major MM3*-based conformers, which are in agreement
with the experimental data, is given in Figure 3.
Thus, in principle, and according to their conformational
behavior in solution, compounds 7–9 can act as mimetics of
the natural glycopeptides, with exo-anomeric orientation for
the corresponding F glycosidic linkage of 9. Indeed, a super-
imposition of compound 8 with GalNAcaOSer (Figure 4) il-
lustrates a remarkable match of the chairs and the positions
of the polar groups of both compounds. To test whether this
similarity will in fact translate into bioactivity, we proceeded
to perform interaction studies with the plant-toxin-reactive
b1–3-linked galactosides.[7,19]
Interaction with viscumin : Saturation transfer difference
(STD) NMR spectra[20] of 7 and 8 in the presence of the ga-
ACHTUNGTRENNUNGlac ACHTUNGTRENNUNGtoside-specific viscumin (VAA) were recorded (Figure 5).
Two molar ratios for the 7/VAA or 8/VAA mixture were
tested, that is, 20:1 and 50:1. Major saturation transfer to
the protons in the pyranose ring was observed, followed by
minor transfer to H3 at the lactam ring, with basically no
transfer to H2 at this fragment. Thus, the recognition mainly
involved the galactose moiety. Moreover, competitive STD
experiments with lactose, a common ligand for VAA known
to enter the lectin sites, were performed. It was shown that
both 7 and 8 competed with lactose for the contact site; this
underscored their bioactivity as lectin ligands.
Further STD NMR assays[21] on 9 in the presence of viscu-
min were also performed (Figure 6). As above for the inter-
actions between 9 and this receptor, but now with ligand/re-
ceptor molar ratios between 30:1 and 200:1, major satura-
tion transfer to the protons in both galactopyranose rings
was observed, especially for the nonreducing end. No trans-
fer to the amino acid protons was evidenced even after long
saturation times; this indicates intimate contact of the lectin
to the sugar moiety of 9. Again, competition experiments
with lactose revealed that both molecules target the same
binding site in the lectin.
To rationalize the interaction on the molecular level, the
low-energy conformers of 7–9, as deduced from NMR ex-
periments, were docked into the lectin sites by the program
Autodock. Two sites are known in the lectin dimer, charac-
Table 2. Chemical shifts and coupling constants of compound 9, mea-
sured in D2O (500 MHz, 298 K, phosphate buffer: 20 mm, pH 5.8).
Proton d
(ppm)
J [Hz] Proton d (ppm) J [Hz]






H-2 3.57 J2,3=11.1 H-2’ 3.55 –
H-3 3.95 J3,4=3.2 H-3’ 3.61 –
H-4 4.16 – H-4’ 3.82 J3,4=3.5
H-5 4.14 – H-5’ 4.16 –













Figure 3. A) The major conformers of 9 (R configuration for Ca) according to the experimental NMR data and MM3*-based molecular mechanics and
dynamics calculations. The orientation around the glycosidic linkage is defined by the exo-anomeric effect, while, according to MD simulations, mobility
is allowed for Y angle, with a concomitant effect on the lactam ring. A superimposition of the two conformers shown left and right is given in the central.
This moiety, in turn, may also adopt the two geometries shown in Figure 1, for 7 and 8. B) The major conformer of 9 (S configuration for Ca) according
to the experimental NMR data and MM3*-based molecular mechanics and dynamics calculations.
Figure 4. Superimposition of the major conformer of 8 with that of Gal-
NAcaOSer. The positions of chair constituents perfectly match each
other. Different orientations of the polar groups of both compounds are
evident, although the existing flexibility might let them occupy similar re-
gions of the conformational space.
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terized by the central presence of Trp38 in the 1a subdo-
main and by Tyr249 in the 2g subdomain.[22] With emerging
insights into pH-dependent changes when comparing the
crystal structure obtained at acidic pH with experimental
binding data under physiological condition, a slight modifi-
cation of the architecture of the site in the 2g subdomain
was inferred.[22,23] The 4C1 conformer fitted very well, espe-
cially in the Trp binding site when geometry A was em-
ployed for the lactam ring. The superimposition of the Gal
rings of 8 and 9 of the Autodock solution with that of lac-
tose in the X-ray structure was excellent. In contrast, Auto-
dock did not find a lactose-type structure for the other site
in viscumin for 8, although manual docking could be accept-
able. Conformer B of 8, on the other hand, could not be ac-
commodated at either site (Figure 7) due to steric repulsion
of the carboxy group with the
protein backbones side chains.
For geometry A, the two meth-
ylene H2a and H2b protons
were oriented outside of the
protein, thus precluding their
contact, as inferred from the
STD experiments. Therefore,
there is a perfect match be-
tween the molecular modeling
results and the experimental
data for bound 8. A similar
conclusion was deduced for the
docking of 9, although in this
case the extension of the addi-
tional galactose moiety permit-
ted docking for any conformer
at the lactam ring as well as re-
taining conformational flexibili-
ty at the interglycosidic torsion
angles (Figure 8). Indeed, the
docked structure perfectly ex-
plains the experimental STD data for the galactose hydro-
gens (with the obvious limitations arising from overlapping)
and the lack of STD effect for protons at the lactam
moiety). These computational data thus establish a structur-
al concept for the experimental data obtained by STD
NMR experiments.
Conclusion
The presented facile synthetic route not only afforded dia-
stereoselectivity, but also a product that maintains the bio-
mimetic conformational properties of the resulting scaffold,
as documented by combined molecular modeling and NMR
spectroscopic analyses. The sugar part retains bioactivity for
Figure 5. A) Compound 7 interacts with viscumin, inhibitable by lactose, via the galactose epitope and with
similar affinity, that is in the millimolar range. The concentration of the protein was 25 mm. The bottom part
shows the 500 MHz 1H NMR spectrum of 7. At the top is the STD spectrum of 7 (2 s saturation time) in the
presence of VAA. The 7/VAA molar ratio is 50:1. The off-resonance frequency was set at 50 ppm, while the
on-resonance frequency was established at 0.5 ppm. B) The STD percentages assigned to the particular hy-
drogens. The 78% value below H3’ Gal corresponds to the addition of H3’ and both H6’ protons.
Figure 6. Compound 9 interacts with viscumin, mainly through the nonreducing galactose moiety, as can be observed in the STD spectra, and in the mo-
lecular scheme, where the key STD percentages are given. The concentration of the protein was ca. 15 mm. The experiments were performed at 298 K, in
20 mm phosphate buffer at pH 5.8. A) An expanded view of the sugar region with a superimposition of the regular 500 MHz 1H NMR spectrum of 9
(top) onto two STD spectra recorded with 100:1 and 50:1 molar ratios of ligand/VAA, which yielded analogous results. The off-resonance frequency was
set to 50 ppm, while the on-resonance frequency was established at 0.5 ppm. B) The STD percentages for 9. The 76% value corresponds to the addition
of H4 and H5 of the reducing Gal unit, and H5’ of the nonreducing Gal. Negligible STD effects on the protons of the lactam moiety are observed, inde-
pendently of the diastereomer at the amino acid chiral center.
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the tested model lectin, so this synthetic scaffold is suitable
to present functionally potent docking sites for clinically rel-
evant human lectins, such as the selectins mentioned in the
introduction. The selectivity for the prepared Galb1–3Gal
sugar moiety among the adhesion/growth-regulatory galec-
tins, with preference for galectins-3 and -9, encourages fur-
ther testing at this level of structural complexity, at which
formation of a C-glycoside could even afford a nonhydrolyz-
able galectin ligand.[24]
Experimental Section
Molecular modeling : The low-energy conformers were calculated by
using the MM3* force field,[13] in Maestro.[25] The six-membered ring cis-
fused to the pseudogalactose moiety through C1 and C2 is rather rigid.
Therefore, only a low level of flexibility remains for the lactam moiety.
Two torsion angles were evaluated to account for the six-membered
ring’s shape, namely for 8, torsion angle f1 is defined as N4-C3-C2-C1
and f2 as C5-N4-C3-C2. For all the molecules, the molecular-dynamics
simulations were performed by using the MM3* force field. A tempera-
ture of simulation of 300 K was employed with a time step of 1.5 fs and
an equilibration time of 100 ps. The total simulation time for each com-
pound was 5 ns. In all the molecular-mechanics and -dynamics calcula-
tions, the GB/SA solvation model for water was used.[26] For 9, different
initial geometries of the F/Y glycosidic linkages were used, with syn or
anti conformers for both F and Y angles. Also, the two possible epimers
at the chiral centre of the amino acid were used as starting geometries, as
well as the two possible geometries of the lactam ring, previously de-
duced for 7 and 8 (see text).
For the C5C6 torsion of the Gal moieties, only the gt geometry (w, de-
fined as C4-C5-C6-O4 ca. 1808) was considered, since it has been demon-
strated to be the major one for galactose derivatives (O4 in axial orienta-
tion).[15,27]
Figure 7. The putative binding mode of compound 8 in complex with vis-
cumin, according to AUTODOCK calculations. The expansion of the lec-
tins Trp site shows interaction with 8 in the preferred A-type conforma-
tion. The methylene protons are not in contact with the polypeptide, in
agreement with the STD observations, which mainly indicate transfer to
the Gal protons. The side chains of the key amino acids interacting
through hydrogen bonds or van der Waals contacts with 8 are shown in
ball and stick form.
Figure 8. Different possibilities for the binding mode of compound 9 to VAA, according to AUTODOCK calculations. The expansion of the Trp site of
VAA is shown in panels (B)–(E). The Tyr site is outlined in panels (A) and (F), with the two different possible epimers of the lactam ring. There is not
any hindrance for the recognition of any of them. Panel (B) shows a superimposition of two conformers around the glycosidic torsion angles of the disac-
charide, while panels (C) and (D) depict the two geometries separately. Panel (E) presents a superimposition of the pose shown in (C) with the crystallo-
graphic binding mode of lactose, showing a good match. All these structures perfectly match the experimental STD data, which are mainly observed at
the Gal moiety, with no transfer to the lactam hydrogens. Indeed, the methylene protons point outside the polypeptide chain. The side chains of the key
amino acids interacting through hydrogen bonds or van der Waals contacts with 9 are shown as sticks.
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NMR experiments with free compound : 1H NMR spectra were recorded
on Bruker Avance 500 spectrometers in D2O with concentrations of
5 mm. Chemical shifts are reported in ppm with external TSP (2,2,3,3-tet-
radeutero-3-trimethylsilylpropionic acid, 0 ppm) as reference. Vicinal
proton–proton coupling constants were estimated from first-order analy-
sis.
2D TOCSY experiments (30 and 70 ms mixing times) were performed by
using a data matrix of 256	2K to digitize a spectral width of 5000 Hz.
Eight scans were used per increment, with a relaxation delay of 2 s.
2D NOESY (600 and 1000 ms) and 2D T-ROESY experiments (400 and
500 ms) used the standard sequences. Distances were estimated from
NOESY/ROESY experimental data by using the isolated spin-pair ap-
proximation[28] for the data with decreased mixing time and averaging.
Estimated errors were below 10%.
A comparison between the observed NOEs and those derived computa-
tionally for the different conformations was performed by using a full-re-
laxation-matrix approach, with a home-made program, which is available
from the authors upon request.[27] For all molecules, an average effective
correlation time of 150 ps was estimated for the best adjustment of the
observed and calculated cross peaks.
Interaction studies with viscumin : The lectin was isolated from extracts
of dried mistletoe leaves, with affinity chromatography on lactosylated
Sepharose 4B as a crucial step. The purity and quaternary structure were
ascertained by one- and two-dimensional gel electrophoresis, gel filtra-
tion and ultracentrifugation; carbohydrate-dependent activity was tested
by hemagglutination as well as solid-phase/cell assays.[29] The binding of
the different compounds was evaluated by STD experiments, which were
performed without saturation of the residual HDO signal for molar
ratios of 20:1 and 50:1 of compound/VAA for 8, and of 30:1 and 200:1 of
compound/VAA for 9. The concentration of the protein was 25 mm. A
series of Gaussian-shaped pulses of 50 ms each was employed with a
total saturation time for the protein envelope of 2 s and a maximum B1
field strength of 60 Hz. An off-resonance frequency of d=40 ppm and an
on-resonance frequency of d=1.0 ppm (protein aliphatic signals region)
were applied. Competition experiments with lactose were also per-
formed. In these cases, a threefold excess of lactose relative to 8 was
added to the solution containing the VAA/8 mixture, and the STD ex-
periment was repeated. For the other compounds, analogous experiments
were performed. In all cases, a decrease in the STD signals of the mimet-
ic compound was observed, thus indicating competition for the same
binding sites.
For the VAA/8 and VAA/9 samples, exchange-transferred NOE experi-
ments (trNOE)[30] were performed by using selective 1D experiments
with the double pulse field-gradient spin-echo (DPFGSE) module.[31]
Measurements were performed on a freshly prepared ligand/lectin mix-
ture, with mixing times of 100 and 200 ms, at an approximately 20:1
molar ratio of ligand/protein for 8 and 40:1 for 9. The ligand concentra-
tion of 2 mm was kept in all cases. No purging spin-lock period was em-
ployed to remove the NMR signals of the macromolecule background.
Strong negative NOE cross peaks were observed, in contrast to the free
state; this indicated binding of the sugars to the lectin preparation.
Docking calculations : The conformers of 8 and 9 (as observed by NMR)
were docked into the two carbohydrate-binding sites of VAA in the 1a
and 2g subdomains of the B-subunit of VAA (PDB ID: 1PUM). The dif-
ferent conformational possibilities of compounds 8 and 9 (see text) were
used as input geometries for Autodock 3.0 simulations[32] with the multi-
ple Lamarckian genetic algorithm. Only local searches were performed
centered around the two known lectin sites of viscumin. Grids of probe-
atom interaction energies and electrostatic potential were generated by
the AutoGrid program present in Autodock 3.0. Grid spacings of 0.6 and
0.375 
 were used for the global and local searches, respectively. For
each calculation, 100 docking runs were performed on a population of
200 individuals and an energy evaluation number of 3	106.
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12 but also  for all  the MMPs  investigated. Furthermore,  the evolution of  the  15N‐1H HSQC  spectra 
upon the addition of unlabeled avidin to solution of 15N MMP‐12 clearly showed that the fourteen‐
member  spacer used  to  link  the biotin unit  to  carboxylic aryl  sulfonamide  inhibitor 1 ensures  the 
simultaneous  binding  of  the  two  proteins  without  permitting  large  interprotein  mobility.  SPR 
analyses  clearly  showed  the  ability of 4  to bind  the  functional  active enzyme MMP‐12  and  avidin 
side‐by‐side.  This  simultaneous  interaction  did  not  affect  negatively  the  nanomolar  affinity  of 
inhibitor 4 for MMP‐12, given that the SPR data nicely reproduced the fluorimetric values measured 
for the BTI 4‐MMP‐12 complex. 
  We  developed  a  new  drug  delivery  system  for  the  Dry‐Eye  Syndrome  (DES),  a  pathology 
affecting a significant percentage of the population, especially people older than 40 years of age. We 
introduce  on  a  appropriate  carrier  (in  our  case  different  PAMAM  dendrimers)  a  broad‐spectrum 
inhibitor  of matrix metalloproteinases,  in  order  to  inhibit  the  activity  of MMPs  that  are  deeply 




a  multigram  scale  and  presented  a  very  good  affinity  for  MMP‐7,  that  it  is  one  of  the  matrix 
metalloproteinases  that  has  a  critical  role  in  tumour  invasion,  and  is  often  expressed  in 
gastrointestinal cancers. Moreover,  it presents a fundamental role  in the early tumor development. 
For  these  reasons  compound  52 will  be  tested  against  colon  cancer,  in  collaboration with Dr.  L. 
Vannucci of the University of Prague.  
  Finally, we  reported  a  family  of  new  high‐affinity MMP  inhibitors  that was  designed  and 
synthesized by using  a conceptually novel strategy whereby a glycosidic residue was introduced on a  
suitable  MMPI.  These  new  carbohydrate‐based  inhibitors,  unprecedented  in  the  NNGH  family, 
display nanomolar affinity  toward  several MMPs and do not appreciably  interact with HSA. These 
inhibitors are a prototype structure that open the way to the design of a new class of highly effective 
MMPIs. Moreover we had synthesized and tested a new group of high affinity, low molecular weight 
MMPIs. These  inhibitors presented an hydrophilic  residue,  that has been appropriately  inserted  to 




















































recorded  on  Melting  Point  Büchi  510.  Optical  rotations  were  determined  with  Jasco  DIP‐370 
polarimeter. Elemental analysis were performed with Elementar analyzer 2400 serie II Perkin‐Elmer 






  The cDNA encoding  the catalytic domain of  the MMP‐12  (G106‐G263) was cloned  into  the 
pET21a  (Novagen)  using  the  restriction  enzymes  Nde  I  and  Xho  I  (New  England  BioLabs).  One 
additional Methionine at position 105 was present  in  the  final expression product. The expression 
vector encoding  for  the protein was  transformed  into  competent Escherichia  coli BL21  (DE3) Gold 
strain  and  colonies  were  selected  for  Ampicillin  resistance.  Bacteria  were  grown  in  LB medium 
containing 50 μg/mL Ampicillin in a shaker flask at 37°C. Protein expression was induced with 0.5 mM 
IPTG at an OD600 = 0.6 and cell growth was continued for a further 5 hours. For expression of 15N 
and  13C‐enriched  protein,  the  bacteria  were  grown  in minimal medium  containing  15N  enriched 
(NH4)2SO4  and 









  Protein was  purified with  Ion  Exchange  chromatography  using  HiTrap  SP  column  using  a 
gradient of NaCl up to 350mM (6 M Urea, 20 mM Sodium Acetate, pH 5). The purified protein was 
refolded by serial dilution method. The protein was diluted to a final concentration of 0.10 mg/mL in 






against  same buffer  (4 M Urea,  20 mM  Tris‐HCl, pH  7.2,  10 mM CaCl2,  0.1mM  ZnCl2,  0.3M NaCl) 
successively followed by two steps with Buffer B (2 M Urea, 20 mM Tris pH 7.2, 10 mM CaCl2, 0.1 mM 
ZnCl2, 0.3 M NaCl) for 8 hours, then finally 3 step of 8 hours each with Buffer C (20 mM Tris pH 7.2, 
10 mM  CaCl2,  0.1mM  ZnCl2,  0.3M NaCl,).  The  protein  solution was  concentrated  up  to  5 ml  and 
purified  by  size  exclusion  chromatography  using  High  LoadTM  16/60  SuperdexTM  75  (Amersham 
Biosciences) and eluted with 20 mM Tris pH 7.2, 10 mM CaCl2, 0.1 mM ZnCl2, 0.3 M NaCl and 0.2 M 










  The  data  were  measured  in‐house,  using  a  PX‐Ultra  copper  sealed  tube  source  (Oxford 
Diffraction). All the datasets were collected at 100 K and the crystals used for data collection were 
cryo‐cooled without  any  cryo‐protectant  treatment. The  crystals of  all  complexes had  a mosaicity 
ranging from 0.6° to 0.8° and diffracted to a maximum resolution of 1.7 Å.   All the soaked adducts 
crystallize in the C2 space group with one molecule in the asymmetric unit.  
The data were processed  in all cases using  the program MOSFLM  [1] and scaled using  the program 
SCALA  [2] with  the TAILS and SECONDARY corrections on  (the  latter  restrained with a TIE SURFACE 
command)  to  achieve  an  empirical  absorption  correction.  Table  1  shows  the  data  collection  and 
processing statistics for all datasets.  
  The structures of the all adducts were solved using the molecular replacement technique; the 
model used was  that of a molecule of human MMP‐12  (1Y93)  from where  the  inhibitor, all water 
molecules and ions were omitted. The correct orientation and translation of the molecule within the 




two  inhibitors  in  the  electron  density. Water molecules  have  been  added  by  using  the  standard 















































  To assess  the binding properties of  compounds 1, 2, 4 and 10  their abilities  to  inhibit  the 
hydrolysis  of  fluorescence‐quenched  peptide  substrate  Mca‐Pro‐Leu‐Gly‐Leu‐Dpa‐Ala‐Arg‐NH2 
(Biomol,  Inc.)  [11] were  tested.  The  analyses were  carried  out  at  298  K  in  50 mM  HEPES  buffer, 
containing 10 mM CaCl2, 0.05% Brij‐35, at pH 7, using 1 nM of MMP catalytic domains and 1 μM of 
peptide.  The  experiments were  performed with  peptide  concentration much  lower  than  Ki.  The 
























7.75  (part MM' of an AA'MM' system,  JAM = 8.4 Hz, 2H), 7.68‐7.34  (m, 5H), 
3.90‐3.82 (m, 1H), 1.81‐1.68 (m, 1H), 1.54‐1.46 (m, 2H), 0.90 (d, J = 7.0 Hz, 
3H),  0.83  (d,  J  =  6.2  Hz,  3H)  ppm.  13C NMR  (50 MHz,  CD3OD):  δ  173.97, 




























  To  a  solution  of  (R)‐methyl  2‐(4‐methoxyphenylsulfonamido)propanoate  (500  mg,  1.18 
mmol) in 1 mL of CH3OH a solution of KOH (1M, H2O; 304 mg, 5.43 mmol) was added. After 72 h, HCl 




M.p.  90‐92  °C.  [α]25D  +17.0  (c  0.34,  CH3OH).  Anal.  Calcd  for  C10H13NO5S:  C, 
46.32; H,  5.05;  5.40.  Found;  C,  46.67; H,  5.51; N,  5.77.  1H NMR  (200 MHz, 
CD3OD) δ 7.83‐7.78 (part AA' of an AA'MM' system, J AM = 8.8 Hz, 2H), 7.08‐7.04 
(part MM' of an AA'MM' system, J AM = 8.8 Hz, 2H), 3.88 (s, 3H), 3.62 (q, J = 7.4 
































neutralized  with  HCl  (3%,  H2O)  and  washed  with  brine  (3x).  The  organic  layer  was  dried  over 
anhydrous Na2SO4 and the solvent was removed  in vacuo to give 8.00 g of a pale yellow solid. The 





CDCl3)  δ 7.93‐7.89  (part AA' of an AA'MM'  system,  JAM = 8.4 Hz, 2H), 7.73‐
7.69  (part MM' of an AA'MM' system,  JAM = 8.4 Hz, 2H), 7.64‐7.44  (m, 5H), 
5.07 (d,   J = 10.2 Hz, 1H), 4.05‐3.93 (m, 1H), 3.43 (s, 3H), 1.89‐1.72 (m, 1H), 
1.59‐1.48 (m, 2H), 0.93 (d, J = 3.2 Hz, 3H); 0.90  (d, J = 2.8 Hz, 3H) ppm.  13C 
















































solvent  was  removed  in  vacuum  and  the  solution  was  lyophilized.  The  solid  obtained  was  re‐











25H), 0.93  (at,  J = 6.4 Hz, 6H) ppm.  13C NMR  (50 MHz, CD3OD)  δ 176.04, 174.39, 164.51, 144.75, 

























































M.p.  : 174‐175  °C;  1H NMR  (200 MHz, CDCl3)    δ 6.17‐
6.07 (m, 2H), 4.70‐4.56 (m, 1H), 4.55‐4.49 (part A of an 
ABMN system, JAB = 8.0 Hz, JAM = 4.4 Hz, 1H), 4.36‐4.29 
(part B of ABX  system,  JAB = 8.0 Hz,  JBX   = 4.6 Hz, 1H), 










































  A  solution  of  CF3COOH  (1.90  mL,  23.8  mmol)  in  dry  CH2Cl2  (6.20  mL)  was  added  to  a 
suspension of  6 (480 mg, 1.08 mmol) in dry CH2Cl2 (4.6 mL). After 1.5 h, 10 mL of toluene were added 
and  solvent was  removed  in  vacuum  to  give pale  yellow oil.  The oil was  repeatedly washed with 
CH3OH  and  CHCl3;  the  compound  7  (490 mg,    >90%)  so  obtained was  used without  any  further 
purification.    
 
1H‐NMR  (200 MHz,  CD3OD);  δ  4.53‐4.47  (part  A  of  an 
ABMN system,  JAB = 8.0 Hz, 1H), 4.33‐4.27  (part B of an 
ABX system, JAB = 8.0 Hz, JBX = 4.4 Hz, 1H), 3.23‐3.14 (m, 
3H),  3.00‐2.87  (m,  5H),  2.73‐2.67  (part M  of  an  AMN 
system, JMN   = 12.4 Hz, 1H), 2.20 (t, J = 7.2 Hz, 2H), 1.72‐




































  To  a  solution  of  3  (600  mg,  1.66  mmol),  6‐bromo‐1‐hexanol  (450  mg,  2.49  mmol)  and 
triphenilphosphine  (872 mg, 3.32 mmol)  in 17 mL of dry THF, 0.65 mL of DIAD  (1.66 mmol) were 
added drop‐wise, in 1 h. The reaction was stirred at rt for 43 h, and then the solvent was removed in 
vacuo to give yellow oil. After crystallization of the betainic side product (EtOAc/ciclohexane 1:8) the 










(m,  6H)  ppm.  13C NMR  (50 MHz,  CDCl3)  δ  171.66,  145.27,  139.23,  138.26, 



























































































































M.p.  93‐94  °C.  ESI‐MS  [M+H]+  calcd  698.35. 
Found 698.30. 1H NMR (200 MHz, CD3OD) δ 7.78‐7.70 
(part  AA'  of  an  AA'MM'  system,  JAM  =  9.2  Hz,  2H); 
6.95‐6.94  (part MM' of an AA'MM'  system,  JAM = 9.2 
Hz, 2H); 4.58‐4.47 (m, 2H); 4.38‐4.32 (part B of an ABX 
system, JAB = 7.8 Hz, JBX = 4.4 Hz, 1H); 3.88 (s, 3H); 3.55 
















































THF, DIAD  (1.44 mL,  7.32 mmol) were  added  dropwise  in  1  h.  The  reaction was  stirred  at  room 
temperature for 16.5 h, then the solvent was removed  in vacuo to give 5.00 g of a yellow oil. After 
removal of crystalin betain  (EtOAc/ciclohexane 1:8)  the  filtrate was concentrated  in vacuo and  the 






















































mg, 0.50 mmol)  in DMF  (1 mL) were  finally  added  and  the mixture was  stirred  for 48 h  at  room 





AA'  of  an AA'MM'  system,  JAM  =  9.2 Hz,  2H);  6.95‐
6.94  (part MM' of an AA'MM'  system,  JAM = 9.2 Hz, 
2H); 4.58‐4.47  (m, 2H); 4.38‐4.32  (part B of an ABX 
system,  JAB = 7.8 Hz,  JBX = 4.4 Hz, 1H); 3.88  (s, 3H); 
3.55  (s,  3H);  3.26‐3.14  (m,  5H);  3.03‐2.87  (m,  5H); 
2.72‐2.69 (part N of an AMN system, JMN = 12.6 Hz, 1 H); 2.20 (t, J = 7.0 Hz, 2H); 1.72‐1.29 (m, 25 H ) 
















































































+ Et3N, DMAPCH2Cl2, 97%
 
To a stirred suspension of 61 (1.00 g, 6.42 mmol) in CH2Cl2 (35 mL) 2.66 mL of NEt3 (19.3 mmol) were 
added  at 0°C.  The  suspension was  stirred  at  room  temperature  for 30’,  cooled  to 0°C  then para‐
















































HCl  (3%,  H2O)  and  then was washed with  brine  (2x).  The  organic  phase was  dried  over  Na2SO4. 










































  To  a  solution  of  14  (555  mg,  1.38  mmol),  N‐Z‐ethanolamine  (322  mg,  1.65  mmol)  and 







was  removed  in  vacuo  to  give  an  yellow  oil.  After  crystallization  of  the  betainic  side  product 


























































 [α]25D    +42.6  (c  0.23,  CHCl3).  ESI‐MS.  [M+Na]
+  calcd  489.13.  Found  489.17. 
[M+K]+  calcd 505.10.  Found 505.08.  1H NMR  (200 MHz, CDCl3):  δ 7.76‐7.68 
(AA’ part of an AA’MM’ system, JAM  = 8.8 Hz, 2H), 7.36‐7.26 (m, 5H); 6.97‐6.89 
(MM’ part of an AA’MM’ system, JAM   = 8.8 Hz, 2H), 5.63‐5.54 (m, 1H), 5.14‐
5.08  (A part of an AB system,  JAB   = 12.2 Hz, 1H), 5.08‐5.01  (B part of an AB 
system, JAB  = 12.2 Hz, 1H), 4.61‐4.56 (dd, J  = 4.4 Hz, J  = 6.6 Hz, 1H), 4.19‐3.84 



















































































































Found  604.25.  [M+K]+  calcd  620.13.  Found  620.08.  1H 
NMR  (200  MHz,  CDCl3):  δ  8.30‐8.21  (AA’  part  of  an 
AA’MM’ system,  JAM   = 9.2 Hz, 2H), 7.75‐7.68  (AA’ part of 
an AA’MM’ system, JAM  = 8.6 Hz, 2H), 7.31‐7.27 (MM’ part 






















































































































  A  suspension of KOH  (19.0 mg, 0.34 mmol)  in 300 µL of CH3OH was  refluxed  for 15’,  then 
NH2OH
.HCl  (16.0 mg,  0.23 mmol) was  added  and  the  suspension was  stirred  at  40  °C  for  5’.  This 
suspension  was  added  to  20,  and  reaction  mixture  was  stirred  for  1  h  then  was  filtered  and 


























  A  suspension  of  KOH  (96.0  mg,  1.71  mmol)  in  560  µL  of  CH3OH  and  a  suspension  of 
NH2OH
.HCl (79.0 mg, 1.14 mmol) in 1.00 mL of CH3OH were refluxed for 15’, then the solution of KOH 
was  added  to  the  solution  of  NH2OH
.HCl  and  the  suspension  was  stirred  at  40  °C  for  10’.  This 













8.8 Hz, 2H), 7.07‐7.04  (MM’ part of  an AA’MM’  system,  JAM    = 8.8 Hz, 2H), 




































Celite®. Evaporation of  the  solvent under  reduced pressure gave  the crude product  that was used 
without further purification. The crude was redissolved in CH2Cl2 (3 mL) and then NMM (120 µL, 1.10 
mmol)  and Ac2O  (104 µL, 1.10 mmol) were  added  at  room  temperature. The mixture was  stirred 
overnight, then it was diluted with CH2Cl2 (100 mL) and washed with H2O (2x). The organic layer was 
dried over anhydrous Na2SO4 and the solvent was removed in vacuo to give a crude product (220 mg) 
















































































































  A  suspension  of  KOH  (60.0  mg,  1.06  mmol)  in  350  µL  of  CH3OH  and  a  suspension  of 
NH2OH
.HCl (49.0 mg, 0.71 mmol) in 590 µL of CH3OH were refluxed for 15’, then the solution of KOH 
was  added  to  the  solution  of  NH2OH
.HCl  and  the  suspension  was  stirred  at  40  °C  for  10’.  This 





























  To  a  solution  of  14  (700 mg,  1.73 mmol),  N‐Z‐pentanolamine  (494 mg,  2.08 mmol)  and 







was  removed  in  vacuo  to  give  an  yellow  oil.  After  crystallization  of  the  betainic  side  product 



























































6.94  (MM’ part of an AA’MM’  system,  JAM   = 8.8 Hz, 2H), 5.10  (A2  system, 
































added  (92.0 mg,  50% wt.).  The mixture was  stirred  at  room  temperature  for  19  h,  then  it was 





















































The  crude  product was  redissolved  in  CH2Cl2  (100 mL)  and washed with  a  saturated  solution  of 
NaHCO3  (3 x 20 mL) and  then with water  (1x). The organic  layer was dried over anhydrous Na2SO4 
and the solvent was removed  in vacuo to give a crude product that was purified by a flash column 
chromatography on silica gel  (CHCl3  then CHCl3/CH3OH 15:1)  to afford 29  (397 mg, 82%  ) as a pale 
yellow oil. 
 
[α]25D    +37.6  (c 0.21, CHCl3).  ESI‐MS.  [M+Na]
+  calcd 
646.20.  Found 646.25.  [M+K]+  calcd. 662.18.  Found 
662.17.  1H NMR  (200 MHz, CDCl3): δ 8.30‐8.22  (AA’ 
part of an AA’MM’ system,  JAM   = 9.2 Hz, 2H), 7.80‐
7.72  (AA’ part of an AA’MM’  system,  JAM   = 8.8 Hz, 
2H), 7.32‐7.24  (MM’ part of an AA’MM’ system,  JAM  
=  9.2  Hz,  2H),  7.00‐6.92  (MM’  part  of  an  AA’MM’ 
system,  JAM   = 8.8 Hz, 2H), 5.74‐5.64  (m, 1H), 4.54‐




















































































































































(MM’ part of an AA’MM’  system,  JAM   = 8.8 Hz, 8H), 4.57‐4.51  (m, 4H), 3.99‐3.79  (m, 8H), 3.87  (s, 








product  (40.0 mg) was purified by a column chromatography on Sephadex LH‐20  resin  (CH3OH)  to 
afford 32 (32.0 mg, 89%) as a colourless oil. 
1H NMR (200 MHz, CD3OD): δ 7.77‐7.7 (AA’ part of an AA’MM’ system, JAM   = 8.8 Hz, 8H), 6.94‐6.93 































organic phase was dried over Na2SO4 and  the solvent was  removed  in vacuum. The crude product 
was used without further purification to afford 33 (118  mg, 83%) as a white solid. 
 
M.p.:  dec.  217°C.  [α]25D  ‐6.33  (c  0.30,  CH3OH).  Anal.  for  C10H13NO6S  calcd:  C, 
43.63; H,  4.76; N,  5.09.  Found:  C,  43.64; H,  4.80; N,  5.07.  1H NMR  (200MHz, 
CD3OD): δ 7.82‐7.77 (AA’ part of an AA’MM’ system, JAM  = 9.2 Hz, 2H), 7.06‐7.01 

































  To a  solution of 41  (703 mg, 1.50 mmol)  in EtOAc/CH3OH 4:1  (12.5 mL), Pd(OH)2  (351 mg, 
50% wt.) was added under inert atmosphere. The mixture was stirred under hydrogen atmosphere at 











































































































temperature  sodium hydrogenocarbonate  (4.32 g, 51.44 mmol) and benzylbromide  (3.36 mL, 28.3 
mmol)  and  the  resulting mixture was  heated  at  reflux  under  nitrogen  atmosphere  for  17  h.  The 
resulting slurry was diluted with water (2x) and extracted with EtOAc(2x). The organic layer was dried 































9.68 mmol)  and MsCl  (1.34 mL,  9.68 mmol).  The  reaction mixture  was  stirred  for  5  h  at  room 
temperature, then was diluited with  CH2Cl2 and washed with a saturated solution of NH4Cl (2x). The 
organic  layer was dried over anhydrous Na2SO4 and  the solvent was  removed  in vacuo  to give  the 













































































PPh3  (715  mg,  2.72  mmol)  and  water  (324  μL,  18.1  mmol).  The  mixture  was  stirred  at  room 













1H NMR  (200 MHz, CDCl3);  δ 7.34‐7.21  (m, 10H), 
3.70‐3.51 (m, 5H), 3.68 (s, 3H); 2.83‐2.74 (dd, J = 5.4, J = 12.8, 1H), 2.68‐2.57 (dd, 
























































































diluited with  150 mL  of  CH2Cl2  and washed with  brine  (2x):  the  organic  layer was  dried  over 
anhydrous Na2SO4 and the solvent was removed  in vacuo to afford 1.20 g of a yellow pale solid. 














































































































and  the mixture was stirred at room  temperature  for 20 h. The reaction mixture was diluited with 
250 mL of CH2Cl2 and washed with HCl  (1%, H2O), NaHCO3 sat. sol. and  finally with water  (2x). The 
organic layer was dried over anhydrous Na2SO4 and the solvent was removed in vacuo to afford 2.30 


































































  To a solution of 44 (250 mg, 0.44 mmol)  in 14 mL of THF/H2O 1:1,   LiOH
.H2O (37.0 mg, 0.88 






system,  JAM  =  8.8 Hz,  2H),  7.03‐6.99  (part MM'  of  an AA'MM' 
system, JAM = 8.8 Hz, 2H), 4.35‐4.24 (m, 1H), 4.15‐4.0.8 (m, 1H), 



































































[M+Na]+  calcd.  903.34,  Found  903.55.  13C 
NMR  (50 MHz, DMSO): 174.5, 171.9, 169.5, 



















































mmol) was  added,  and  the mixture  was  stirred  at  room  temperature  for  17  h.  The  reaction 
mixture was diluited with 150 mL of EtOAc  and washed with brine  (2x):  the organic  layer was 
dried over anhydrous Na2SO4 and the solvent was removed  in vacuo to afford 1.30 g of a yellow 
pale  solid.  The  crude  material  was  purified  by  flash  chromatography  on  silica  gel 
(EtOAc/Petroleum ether 1:1 then EtOAc) to afford 48 as a white glassy solid (912 mg, 67% yield). 
 
Anal.  Calcd  for  C27H37N3O9S:  C,  55.94;  H,  6.43;  N,  7.25.  Found:  C, 
55.54; H, 6.44; N, 7.33. 1H NMR (200 MHz, CDCl3): δ 7.76‐7.68 (part 
AA' of an AA'MM' system, JAM = 8.8 Hz, 2H), 7.37‐7.26 (m, 5H), 6.97‐
























































to a solution of Boc‐Leu‐OH  (336 mg, 1.45 mmol) and NMM  (145 μL, 1.33 mmol)  in dry DMF  (4 
mL) and the mixture was stirred at room temperature for 30 min. HATU (551 mg, 1.45 mmol) was 













































































system,  JAM  =  8.8  Hz,  2H),  7.06‐7.02  (part MM'  of  an  AA'MM' 
system,  JAM = 8.8 Hz, 2H), 4.20‐4.04  (m, 4H), 3.45‐3.34  (m, 2H), 
























































was  stirred  at  room  temperature  for  2  h,  then  toluene  (10 mL) was  added  and  the  solvent was 








































































an AA'MM'  system,  JAM = 9.2 Hz, 2H), 7.08‐7.00  (part MM' of an 
AA'MM' system, JAM = 9.2 Hz, 2H), 4.32 (q, J = 7.00 Hz, 1H), 3.92‐

































































24 h  then a mixture of AcOH/H2O 1:1  (10 mL) was added. The aqueous phase was  separated and 
extracted 4x with  EtOAc.  The  combined organic  layer were dried over  anhydrous Na2SO4  and  the 





system,  JAM  = 8.8 Hz, 2H), 6.99‐6.95  (part MM' of  an AA'MM' 
system, JAM = 8.8 Hz, 2H), 4.26‐4.02 (m, 2H), 3.84 (s, 3H), 3.84‐
3.74  (m, 1H), 3.35‐3.28  (m, 2H), 1.74‐1.24  (m, 15H), 0.94‐0.90 




































  A suspension of KOH  (307 mg, 5.49 mmol)  in 2.5 mL of CH3OH were  refluxed  for 15’,  then 
NH2OH
.HCl  (252 mg,  3.66 mmol)  was  added.  The  suspension  was  stirred  at  40  °C  for  5’  .  This 









methoxyphenylsulfonamido)propanoate  (250  mg,  0.91  mmol)  in  1  mL  of  CH3OH.  The  reaction 
mixture was  stirred  for  18  h  then was  diluted with  EtOAc  (15 mL),  filtered  and  concentrated  to 
















1H  NMR  (200  MHz,  CD3OD):  δ  7.82‐7.78  (part  AA'  of  an 
AA'MM' system, JAM = 8.8 Hz, 2H), 7.10‐7.06 (part MM' of an 
AA'MM'  system,  JAM  =  8.8 Hz,  2H),  4.37  (d,  J  =  8.4 Hz,  1H), 


















1H  NMR  (200  MHz,  CD3OD):  δ  7.84‐7.79  (part  AA'  of  an 
AA'MM'  system,  JAM = 8.8 Hz, 2H), 7.11‐7.07  (part MM' of an 
AA'MM' system, JAM = 8.8 Hz, 2H), 4.20 (d, J = 6.6 Hz, 1H), 4.09‐


































































  To a  stirred  suspension of glycine methyl esther hydrochloride 60  (300 mg, 2.39 mmol)  in 
CH2Cl2 (5 mL) 1.00 mL of NEt3 (7.17 mmol) were added at 0°C. The suspension was stirred at room 









an AA’MM’  system,  JAM   = 8.8 Hz, 2H), 6.99‐6.95  (MM’ part of an AA’MM’ 
system, JAM  = 8.8 Hz, 2H), 5.08‐5.06 (m, 1H), 3.86 (s, 3H), 3.77 (d, J = 5.4 Hz), 



































  To a stirred suspension of 62  (1.00 g, 5.90 mmol),  in CH2Cl2  (20 mL), 2.50 mL of NEt3  (17.7 











4.20‐4.08  (m, 1H), 3.88‐3.76  (m, 1H), 3.53  (s, 3H), 2.48  (d,  J = 5.6 Hz, 1H), 

























































































6:1 were added and  the  suspension was  stirred  for 30’ at  room  temperature. The white  solid was 
filtered off and  the  filtrate was  concentrated  to dryness. The  crude product was purified by  flash 
column chromatography on silica gel (CHCl3/EtOAc 7:1) to afford  67 (1.30 g, 87%) as an oil. 
 
[α]25D:    +4.39  (c  0.41,  CHCl3). HRMS  for  C16H23NO7S+H  calcd:  374.1273. 
Found: 374.1268. 1H NMR (200MHz, CDCl3) : δ 7.77‐7.74 (AA’ part of an 

























































































































































analysis  (18 h),  then  concentrated  to dryness. The  crude product was dissolved  in EtOAc, washed 
with a mixture AcOH/H2O 1:1 and dried over Na2SO4. Concentration of  the  solvent under vacuum 
afford  a  crude  product  which  was  purified  by  HPLC  (C8  column  Ultrasphere  Beckman  Coulter, 
AcCN/H2O 10:90, AcCN/H2O 30:70) to afford 70 (90.0 mg, 45%) as a pale yellow glassy solid. 
 
 [α]25D:    ‐22.3  (c  0.48,  CH3OH). HRMS  for  C12H19N2O7S+H  calcd:  335,0913. 
Found: 335.0909. ESI‐MS [M+H]+ calcd: 335.1. Found: 335.1. [M+Na]+ calcd: 
357.1. Found: 357.1. 1H NMR  (400 MHz, CD3OD)  : δ 7.73‐7.70  (AA’ part of 
an AA’MM’  system,  JAM   = 8.8 Hz, 2H), 7.05‐7.03  (MM’ part of  a AA’MM’ 
system, JAM  = 8.8 Hz, 2H), 3.90‐3.78 (m, 3H, CH2‐2, H‐2’),   3.88 (s, 3H, OCH3), 
3.52‐3.51  (m, 2H, CH‐3’), 3.35‐3.30  (m, 1H, H‐1’a), 3.17‐3.11  (B part of an 



















































of  a mixture  cyclohexane/EtOAc  8:1 were  added  and  the  suspension was  stirred  for  30’  at  room 
temperature. The white solid was filtered off and the filtrate was concentrated to dryness. The crude 



















































and  stirred  for  4  h,  then  toluene  (5 mL) was  added.  Evaporation  of  the  solvent  under  reduced 








































stirred at  room  temperature  for 1h,  then a  solution of a crude mixture of 72 + 73  (0.54 mmol)  in 
CH3OH (2 mL) was added. The reaction mixture was for 15 h then concentrated to dryness. The crude 
product  was  dissolved  in  EtOAc,  washed  with  a mixture  AcOH/H2O  1:1  and  dried  over  Na2SO4. 
Concentration of the solvent under vacuum afford a crude product which was purified by HPLC  (C8 
column  Ultrasphere  Beckman  Coulter,  AcCN/H2O  10:90,  AcCN/H2O  20:80)  to  afford  74  (99.0 mg, 
50%) as a white solid. 
 
[α]25D:    ‐11.0  (c 0.25, CH3OH). HRMS: calcd.  for C13H20N2O8S+H: 365.1019; 
found: 365.1013. ESI‐MS [M+H]+ calcd: 365.1. Found: 365.1. ESI‐MS [M‐H]‐ 
calcd: 363.1. Found: 363.1.  1H NMR  (400 MHz, CD3OD): δ 7.86‐7.83  (AA’ 
part of  an AA’MM’  system,  JAM    =  9.2 Hz,  2H),  7.11‐7.09  (MM’ part of  a 
AA’MM’ system, JAM   = 9.2 Hz, 2H), 4.41‐4.37 (A part of a AXY system,  JAX= 
8.0 Hz, JAY   = 5.5 Hz, 1H, H‐2), 4.14‐4.08 (m, 1H, H‐2’), 3.91 (s, 3H,  ‐OCH3), 





















































  To a stirred suspension of 60  (500 mg, 4.00 mmol)  in CH2Cl2  (5 mL), 1.66 mL of NEt3  (12.0 




Na2SO4 and  the  solvent was  removed  in vacuum. The  crude product was purified by  flash  column 
chromatography on  silica  gel  (petroleum ether/EtOAc 2:1)  to  afford 75  (990 mg, 81%)  as  a white 
solid. 
 
M.p.:  128‐131  °C.  Anal.  for  C15H15NO3S  calcd:  C,  59.00;  H,  4.95;  N,  4.59. 
Found: C, 59.26; H, 4.68; N, 4.32. 1H NMR (200MHz, CDCl3): δ 7.95‐7.91 (AA’ 








































  To a solution of 75  (700 mg, 2.29 mmol), PPh3  (784 mg, 2.98 mmol) and 66  (394 mg, 2.98 
mmol)  in dry  THF  (9 mL) DIAD  (586 µL,  2.98 mmol) was  slowly  added.  The  reaction mixture was 






1H NMR  (200MHz, CDCl3): δ 7.92‐ 7.86  (m, 2H), 7.74‐7.60  (m, 2H), 7.53‐
7.41 (m, 5H), 4.40‐4.18 (m, 3H), 4.12‐4.04 (m, 1H), 3.74‐3.59 (m, 2H), 3.61 
(s,  3H),  3.31‐3.20  (m,  1H),  1.37  (s,  3H),  1.31  (s,  3H).  13C NMR  (50MHz, 














































crude  product which was  purified  by  a  flash  column  chromatography  on  silica  gel  (CH2Cl2/CH3OH 









1H NMR  (200MHz, CD3OD):  δ 7.93‐7.89  (m, 2H),  7.82‐7.78  (m, 2H), 7.70‐
7.65  (m, 2H), 7.52‐7.39  (m, 3H), 4.34‐4.24  (A part of an AB  system,  JAB = 
18.4 Hz), 4.23‐4.14  (B part of an AB  system,  JAB = 18.4 Hz), 3.88‐3.77  (m, 
1H), 3.61  (s, 3H), 3.61‐3.48  (m, 3H), 3.26‐3.15  (m, 1H).  13C NMR  (50MHz, 






































































































product was  dissolved  in  EtOAc  , washed with  a mixture  AcOH/H2O  1:1  and  dried  over  Na2SO4. 




M.p.:  105‐107  °C.  [α]25D:  +23.0  (c  0.30,  CH3OH).  ESI‐MS  [M+Na]
+  calcd. 





































  To a stirred suspension of 60  (1.00 g, 8.00 mmol),  in CH2Cl2  (30 mL), 3.20 mL of NEt3  (16.0 
mmol) were added at 0°C. The suspension was stirred at  room  temperature  for 30’, cooled  to 0°C 
then para‐fluorobenzensulphonyl  chloride  (1.55 g, 8.00 mmol) and DMAP  (catalytic amount) were 







phase was  dried  over  Na2SO4  and  the  solvent was  removed  in  vacuum.  The  crude  product was 
purified by flash column chromatography on silica gel (petroleum ether/EtOAc 1:1) to afford 81 (1.85 
g, 89%) as a white solid. 
M.p.:  125‐128  °C.  Anal.  for  C9H10FNO4S  calcd:  C,  43.72;  H,  4.08;  N,  5.67. 











































































































































0 °C - rt, 48%
 
  To a stirred solution of 75 (500 mg, 1.64 mmol) in DMF dry (2 mL), NaH (43.0 mg, 1.80 mmol) 
was  added  at  0°C  under  a  nitrogen  atmosphere.  The  reaction  mixture  was  warmed  to  room 








vacuum  afford  a  crude  product which was  purified  by  flash  column  chromatography  on  silica  gel 
(petroleum ether/CH2Cl2/EtOAc  2:1:1) to afford 83 (310 mg, 48%) as a colourless oil. 
 
Anal.  for C19H21NO6S  calcd: C,  58.30; H,  5.41; N,  3.58.  Found:  C,  57.56; H, 
5.50; N, 3.39.  1H NMR  (200MHz, CDCl3): δ 7.92‐7.87  (m, 2H), 7.73‐7.69  (m 
2H), 7.63‐7.58 (m, 2H), 7.51‐7.44 (m, 3H), 4.23 (t, J = 5.6 Hz, 2H), 4.20 (s, 2H), 
3.63 (s, 3H), 3.58 (t, J = 5.6 Hz, 2H), 2.00 (s, 3H). 13C NMR (50MHz, CDCl3): δ 




















































































  A suspension of   KOH  (121 mg, 2.15 mmol) and NH2OH
.HCl  (120 mg, 1.72 mmol)  in CH3OH 
(1.5 mL) was  stirred  at  room  temperature  for 1h,  then  a  solution of 82a  (125 mg, 0.43 mmol)  in 
CH3OH (2 mL) was added. The reaction mixture was stirred for 18 h, then concentrated to dryness. 





























































55.37; H, 5.30; N, 8.32.  1H NMR  (200MHz, DMSO‐d6): δ 7.94‐7.82  (m, 4H), 
7.81‐7.77  (m, 2H), 7.59‐7.48  (m, 3H), 3.84  (s, 2H), 3.58  (at,  J = 6.6 Hz, 2H), 




































































for  MMP  Expression  and  Activation:  Design,  Synthesis,  and  Binding  Properties. 
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Biotin-Tagged Probes for MMP Expression and Activation: Design,
Synthesis, and Binding Properties
Elisa Dragoni, Vito Calderone, Marco Fragai, Rahul Jaiswal, Claudio Luchinat,* and Cristina Nativi*
Magnetic Resonance Center (CERM) - University of Florence, Via L. Sacconi 6, 50019 Sesto Fiorentino, Italy, Department of
Organic Chemistry, University of Florence, Via della Lastruccia 13, 50019 Sesto Fiorentino, and Department of Agricultural
Biotechnology, University of Florence, Via Maragliano, 75-77, 50144 Florence, Italy. Received September 8, 2008;
Revised Manuscript Received January 24, 2009
The design and synthesis of biotin chain-terminated inhibitors (BTI) showing high affinity for matrix
metalloproteinases (MMPs) on one side and high affinity for avidin through the biotinylated tag on the other are
reported. The affinity of the designed BTI toward five different MMPs has been evaluated and the simultaneous
formation of a highly stable ternary system Avidin-BTI-MMP clearly assessed. This system will permit the
development of new approaches to detect, quantify, or collect MMPs in biological samples, with potential
applications in vivo.
INTRODUCTION
The design of molecular probes able to selectively bind
biomolecular targets is gaining importance not only for their
applications in molecular biology, but also for the development
of new techniques for the early stage diagnosis and therapy of
several pathologies (1). Rational drug design driven by structural
data is currently applied to speed up the design of new candidate
drugs in pharmaceutical research (2-5). The same approach is
even more important to design molecular probes where, besides
classical requirements, additive structural and functional features
are required.
Matrix metalloproteinases (MMPs), also known as matrixins,
are proteinases that participate in extracellular matrix (ECM)
degradation (6) and in several extracellular processes (7-10).
Under normal physiological conditions, the activity of MMPs
is strictly regulated by transcription/activation of zymogens
precursors, interaction with specific ECM components, and
inhibition by endogenous inhibitors (TIMPs) (11-14). An
imbalance of these activities may results in diseases such as
atherosclerosis, thrombosis, or heart failure (15, 16). As a matter
of fact, expression and activation of MMPs are increased in
these pathologies, as well as in almost all human cancers,
compared to physiological conditions (17). Indeed, ECM
degradation by MMPs does promote tumor invasiveness.
Furthermore, it has been recently demonstrated that MMPs carry
out functions other than promotion of invasion, and that they
likely take part in the development of cancer even before
invasion. Noteworthy, the degree of overexpression of MMPs
in cancer tissues is strictly associated with the level of tumor
invasiveness and with its tendency to form metastasis. It is
therefore apparent that the development of efficient molecular
devices designed to reveal the overexpression of MMPs may
be a powerful tool for the early detection of tumors and the
assessment of their aggressiveness, as well as of cardiocircu-
latory problems (18).
Studies focused on the detection of overexpression of MMPs
have already been reported (19) and probes to profile MMPs in
tissues synthesized and tested (20, 21). In particular, hydrolyz-
able, near-infrared fluorescent molecules have been successfully
tested in mice to detect fibrosarcoma (22). Unfortunately, this
innovative technique suffers from the serious limitation repre-
sented by the limited penetration of light (a few millimeters);
such a degree of penetration is only sufficient for the readout
of superficial subcutaneous tumors (<10 mm).
An interesting approach to detect overexpression of MMP
in atherosclerosis has also been published. Low molecular
weight inhibitors, able to interact with the active site of MMPs
involved in atherosclerotic plaque disruption, have been targeted
with nuclear agents and tested in vivo (23-25). Although the
results reported were extremely encouraging, the approach
presented a scarce flexibility, due to experimental difficulties
in preparing the targeted inhibitors and to limited availability
of suitable nuclear agents.
A significant improvement in the development of MMP-
conjugated probes to detect pathological events may be the
rational design of biotin-labeled inhibitors (26), capable of
binding to MMPs exclusively and with high affinity. These
tagged molecules rely on the well-known avidin-biotin mo-
lecular recognition system and could be used in conjunction
with commercially available biotin-labeled probes (i.e., radio-
nuclide chelates) to efficiently detect pathological tissues by
imaging the local overexpression of MMPs. The use of such
molecules is not limited to in vivo imaging but can be extended
to in vitro applications such as MMP purification by using avidin
columns or devices.
Capitalizing on our expertise on expression and structural
characterization of MMPs (27-29) and on the rational design
and synthesis of MMP inhibitors (30-35), in the present paper
we report the design and synthesis of carboxylic-containing,
biotinylated inhibitors able to show high affinity for MMPs and
at the same time able to strongly interact with avidin through
the biotinylated tag.
In clinical therapy, selectivity of inhibitors for a specific MMP
is dramatically important, so much so that the lack of selectivity
is believed to have been the main reason for failures of clinical
trials in the past. Often, the failure of clinical trials, due to the
severity of the side-effects, was related to the chronic adverse
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effects of nonselective inhibitors. On the other hand, for the
molecules proposed here, selectivity is not an issue as chronic
use is not required. Indeed, ideal probes to detect overexpression
of MMPs must not be selective inhibitors vs a specific MMP,
but they should instead selectively recognize MMPs among
other proteins. These new biotinylated molecules designed to
bind to MMPs and to be recognized by avidin might therefore
be successfully used in the in vitro collection/purification of
MMPs, in the visualization of pathological tissues where MMPs
are overexpressed, and to evaluate the aggressiveness of the
pathology by monitoring, e.g., radioactivity. Moreover, it might
be possible to test in vivo the efficacy of clinical treatments
against a specific disease by just monitoring the level of MMPs
produced during the therapy. In addition, such molecules can
be easily employed for collecting and purifying MMPs from
biological samples.
EXPERIMENTAL PROCEDURES
General. All reagents were commercially available and used
as received. Dry solvents were prepared before use. The catalytic
domain of the MMP-12 (G106-G263) was cloned into the
pET21a (Novagen) using the restriction enzymes Nde I and Xho
I (New England BioLabs). NMR spectra were recorded using a
Varian Gemini 200, Varian Mercury 400 spectrometer, and a
Brucker 700 spectrometer (HSQC). HPLC purification was
performed using Althech Ultrasphere C-18 column (250 × 10
mm) and monitored with a Dionex photodiode array detector.
SPR data were obtained using a BioRad ProteOn XPR36.
(R)-Methyl 2-(N-(bromomethyl)biphenyl-4-ylsulfonamido)-
4-methylpentanoate (8). To a solution of 3 (600 mg, 1.66 mmol),
6-bromo-1-hexanol (450 mg, 2.49 mmol), and triphenylphos-
phine (872 mg, 3.32 mmol) in 17 mL of dry THF, 0.65 mL of
DIAD (1.66 mmol) was added dropwise, in 1 h. The reaction
was stirred at rt for 43 h, and then the solvent was removed in
vacuo to give a yellow oil. After crystallization of the betainic
side product (EtOAc/cyclohexane 1:8), the filtrate was concen-
trated in vacuum and the residue (3.20 g) was purified twice
by flash column chromatography on silica gel (hexane/EtOAc
6:1, then CH2Cl2) to give pure 8 as a white solid (515 mg, 60%
yield).
[R]25D +47.4 (c 1.13, CHCl3). MP: 59-61 °C. 1H NMR (200
MHz, CDCl3) δ 7.90-7.86 (part AA′ of an AA′MM′ system,
JAM ) 8.8 Hz, 2H), 7.72-7.68 (part MM′ of an AA′MM′
system, JAM ) 8.8 Hz, 2H), 7.65-7.40 (m, 5H), 4.63-4.55 (dd,
1H, J ) 5.6 Hz, J ) 6.0 Hz), 3.46 (s, 3H), 3.40 (t, J ) 6.8 Hz,
2H), 3.30-3.06 (m, 2H), 1.97-1.17 (m, 11H), 0.99-0.94 (m,
6H). 13C NMR (50 MHz, CDCl3) δ 171.66, 145.27, 139.23,
138.26, 128.97, 128.38, 127.88, 127.26, 127.20, 58.09, 51.96,
45.95, 39.59, 33.86, 32.75, 31.19, 27.86, 26.36, 24.63, 22.99,
21.73. ESI-MS [M + H]+ calcd 524.14. Found 524.11.
tert-Butyl (5-((4S)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-
4-yl)pentanamido)methylcarbamate (6). A suspension of N-Boc-
1,6-diaminohexane hydrochloride 5 (310 mg, 1.23 mmol) and
NMM (0.14 mL, 1.23 mmol) in dry DMF (3 mL) was added to
a slurry of D-biotin (300 mg, 1.23 mmol) and NMM (0.14 mL,
1.23 mmol) in dry DMF (10 mL), and the mixture was stirred
at rt for 10 min. A solution of HATU (468 mg, 1.23 mmol) in
dry DMF (3 mL) was added, and the mixture was stirred for
3.5 h. The reaction mixture was diluited with 20 mL of CH2Cl2
and washed with water: the organic layer was dried over
anhydrous Na2SO4, and the solvent was removed in vacuo to
give a yellow pale oil. Part of DMF was removed in vacuum to
give 2.20 g of a yellow solid. The crude material was purified
by flash column chromatography on silica gel (CH2Cl2/CH3OH
6:1) to give 6 as a white solid (500 mg, 92% yield).
MP: 174-175 °C. 1H NMR (200 MHz, CDCl3) δ 6.17-6.07
(m, 2H), 4.70-4.56 (m, 1H), 4.55-4.49 (part A of an ABMN
system, JAB ) 8.0 Hz, JAM ) 4.4 Hz, 1H), 4.36-4.29 (part B
of ABX system, JAB ) 8.0 Hz, JBX ) 4.6 Hz, 1H), 3.24-3.10
(m, 5H), 2.97-2.71 (part MN of an AMN system, JMN ) 12.4
Hz, JAM ) 4.4 Hz, 2H), 2.22 (t, J ) 7.0 Hz, 2H), 1.48-1.25
(m, 23H). 13C NMR (50 MHz, CDCl3) δ 173.80, 163.62, 155.91,
62.11, 60.56, 55.56, 40.56, 39.70, 35.65, 30.06, 29.87, 29.27,
28.61, 28.18, 28.09, 26.39, 26.25, 25.84. Anal. (C16H28N4O4S)
C, 51.69; H, 7.62; N, 15.00.
(5-((4S)-2-Oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pen-
tanamido)methanaminium (7). A solution of CF3COOH (1.9
mL, 23.8 mmol) in dry CH2Cl2 (6.2 mL) was added to a
suspension of 6 (480 mg, 1.08 mmol) in dry CH2Cl2 (4.6 mL).
After 1.5 h, 10 mL of toluene was added and solvent was
removed under vacuum to give a pale yellow oil. The oil was
repeatedly washed with CH3OH and CHCl3; the compound 7
(490 mg, >90%) so obtained was used without any further
purification.
1H NMR (200 MHz, CD3OD) δ 4.53-4.47 (part A of an
ABMN system, JAB ) 8.0 Hz, 1H), 4.33-4.27 (part B of an
ABX system, JAB ) 8.0 Hz, JBX ) 4.4 Hz, 1H), 3.23-3.14 (m,
3H), 3.00-2.87 (m, 5H), 2.73-2.67 (part M of an AMN system,
JMN ) 12.4 Hz, 1H), 2.20 (t, J ) 7.2 Hz, 2H), 1.72-1.40 (m,
12H). 13C NMR (50 MHz, CD3OD): 174.45, 164.54, 159.90,
62.07, 60.32, 55.74, 39.77, 39.40, 38.79, 35.54, 28.87, 28.53,
28.27, 27.24, 26.12, 25.75, 25.69.
(2R)-Methyl-4-methyl-2-(N-(((5-((4S)-2-oxohexahydro-1H-
thieno[3,4-d]imidazol-4-yl)pentanamido)methylamino)meth-
yl)biphenyl-4-ylsulfonamido)pentanoate (9). To a solution of
7 (236 mg, 0.69 mmol) in dry DMF (4 mL) were added 4 Å
activated pellets molecular sieves (400 mg). The mixture was
stirred at rt for 1 h. Cesium hydroxide monohydrate previously
dried at 120 °C for 24 h (116 mg, 0.69 mmol) was added, and
the solution was allowed to stir for 30 min. TBAI (250 mg,
0.69 mmol) and compoud 8 (360 mg, 0.69 mmol) was finally
added and the mixture was stirred for 48 h. The crude material
was purified by flash column chromatography on silica gel
(CH2Cl2/CH3OH 6:1) to give 9 (300 mg, 55%) as a pale yellow
solid.
MP: 129-131 °C. 1H NMR (200 MHz, CD3OD) δ 7.91-7.41
(m, 9H), 4.58-4.48 (m, 2H), 4.34-4.28 (part B of an ABX
syst, JAB ) 7.8 Hz, JBX ) 4.4 Hz, 1H), 3.43 (s, 3H), 3.26-3.14
(m, 4H), 3.04-2.74 (m, 6H), 2.21 (t, J ) 7.0 Hz, 2H),
1.73-1.29 (m, 25H), 0.95 (ad, 6H, J ) 5.4 Hz). 13C NMR (50
MHz, CDCl3) δ 174.45, 171.45, 164.47, 145.45, 138.97, 138.03,
128.71, 128.15, 127.70, 127.05, 126.80, 62.07, 60.32, 58.13,
55.72, 51.14, 47.60, 45.71, 39.79, 39.26, 38.73, 35.54, 30.97,
28.94, 28.50, 28.27, 26.18, 26.06, 25.94, 25.84, 25.69, 24.42,
21.93, 20.58. ESI-MS [M + H]+ calcd 786.42. Found 786.50.
(2R)-4-Methyl-2-(N-(((5-((4S)-2-oxohexahydro-1H-thieno[3,4-
d]imidazol-4yl)pentanamido)methylamino)methyl)biphenyl-4-
ylsulfonamido)pentanoic acid (4). To a solution of 9 (143 mg,
0.18 mmol) in 2.8 mL of THF/H2O (1:1 v/v) LiOH ·H2O (15.1
mg, 0.36 mmol) was added and the mixture was stirred for 6 h
at rt, then H3PO4 1 M was added (pH ) 5); the solvent was
removed in vacuum, and the solution was lyophilized. The solid
obtained was redissolved in AcCN/H2O 3:1 and purified by a
reversed-phase semipreparative HPLC to give compound 4 (76
mg, 55%).
[R]25D +38.19 (c 0.33, CH3OH). MP: 119-121 °C. 1H NMR
(400 MHz, CD3OD) δ 7.96-7.38 (m, 9H), 4.49-4.46 (part A
of an ABMN system, JAB ) 8.0 Hz, JAM ) 4.4 Hz, 1H),
4.41-4.37 (m, 1H), 4.30-4.27 (part B of an ABX system, JAB
) 8.0 Hz, JBX ) 4.6 Hz, 1H), 3.49-3.38 (m, 1H), 3.29-3.14
(m, 4H), 2.93-2.88 (m, 5H), 2.71-2.68 (part N of an AMN
system, JMN ) 12.8 Hz, 1H), 2.19 (t, J ) 7.2 Hz, 2H),
1.88-1.22 (m, 25H), 0.93 (at, J ) 6.4 Hz, 6H). 13C NMR (50
MHz, CD3OD) δ 176.04, 174.39, 164.51, 144.75, 139.22,
720 Bioconjugate Chem., Vol. 20, No. 4, 2009 Dragoni et al.
128.64, 127.94, 127.79, 126.80, 126.76, 62.07, 61.02, 60.31,
55.72, 47.51, 45.04, 40.31, 39.77, 38.79, 35.54, 30.38, 28.96,
28.51, 28.27, 26.12, 25.92, 25.68, 25.56, 24.81, 22.17, 21.16.
ESI-MS [M + H]+ calcd 772.41. Found 772.54. Anal.
(C31H45N5O6S2) C, 57.43; H,7.08; N, 10.61.
(2R)-Methyl-2-(4-methoxy-N-(((5-((4S)-2-oxohexahydro-1H-
thieno[3,4-d]imidazol-4-yl) pentanamido)methylamino)meth-
yl)phenylsulfonamido)propanoate (12). To a solution of 7 (170
mg, 0.50 mmol) in dry DMF (2 mL), 4 Å activated pellets
molecular sieves (280 mg) were added, and the mixture was
gently stirred at rt for 1 h. Cesium hydroxide monohydrate,
previously dried at 120 °C for 24 h, (84 mg, 0.50 mmol) was
added, and the reaction mixture was stirred for 30 min. A
solution of 11 (218 mg, 0.50 mmol) and TBAI (182 mg, 0.50
mmol) in DMF (1 mL) were finally added, and the mixture was
stirred for 48 h at rt. The crude material obtained was purified
by flash column chromatography on silica gel (CH2Cl2/CH3OH
6:1) to give 12 (200 mg, 58%) as a pale yellow solid.
MP: 93-94 °C. 1H NMR (200 MHz, CD3OD) δ 7.78-7.70
(part AA′ of an AA′MM′ system, JAM ) 9.2 Hz, 2H), 6.95-6.94
(part MM′ of an AA′MM′ system, JAM ) 9.2 Hz, 2H),
4.58-4.47 (m, 2H), 4.38-4.32 (part B of an ABX system, JAB
) 7.8 Hz, JBX ) 4.4 Hz, 1H), 3.88 (s, 3H), 3.55 (s, 3H),
3.26-3.14 (m, 5H), 3.03-2.87 (m, 5H), 2.72-2.69 (part N of
an AMN system, JMN ) 12.6 Hz, 1H), 2.20 (t, J ) 7.0 Hz,
2H), 1.72-1.29 (m, 25 H). 13C NMR (50 MHz, CD3OD) δ
173.27, 171.80, 163.50, 162.71, 131.39, 129.28, 114.03, 68.21,
61.99, 60.22, 55.72, 55.18, 52.49, 52.26, 45.45, 40.70, 38.06,
35.78, 30.84, 29.85, 28.94, 28.15, 28.07, 26.33, 26.25, 26.03,




yl)phenylsulfonamido)propanoic Acid (10). To a solution of 12
(229 mg, 0.33 mmol) in 4.8 mL of CH3OH/H2O 1:1, LiOH ·H2O
(28.0 mg, 0.66 mmol) was added and the mixture was stirred
for 19 h at rt. A solution of H3PO4 (1 M, H2O) was added (pH
) 5), the solvent was removed under vacuum, and the crude
product was lyophilized. The solid obtained was redissolved in
AcCN/ H2O 3:1 and purified by a reversed-phase semiprepara-
tive HPLC to give compound 10 (53 mg, 23%) as a white solid.
MP: 70-72 °C. 1H NMR (400 MHz, CD3OD) δ 7.80-7.77
(part AA′ of an AA′MM′, JAM ) 9.2 Hz, 2H), 7.04-7.02 (part
MM′ of an AA′MM′ system, JAM ) 9.2 Hz, 2H), 4.50-4.47
(m, 1H), 4.36 (q, J ) 7.2 Hz, 1H), 4.31-4.28 (m, 1H), 3.86 (s,
3H), 3.32-3.26 (m, 1H), 3.21-3.15 (m, 4H), 2.98-2.90 (m,
5H), 2.72-2.68 (part N of an AMN system, JMN ) 12.4 Hz,
1H), 2.19 (t, J ) 7.2 Hz, 2H), 1.70-1.30 (m, 22H), 1.20 (d, J
) 7.2 Hz, 3H). 13C NMR (50 MHz, CD3OD) δ 176.67, 174.39,
164.51, 162.68, 132.33, 129.02, 113.65, 62.07, 60.31, 57.73,
55.74, 54.83, 47.60, 44.68, 39.80, 38.80, 35.54, 29.84, 29.00,
28.51, 28.29, 26.13, 25.95, 25.70, 25.59, 25.53, 25.37, 16.16.
ESI-MS: [M + H]+ calcd 684.34. Found 684.30. Anal.
(C23H37N5O7S2) C, 49.47; H, 6.60; N, 12.70.
RESULTS AND DISCUSSION
Aryl-sulfonamide derivatives have been largely exploited to
synthesize broad-spectrum MMP inhibitors. These scaffolds
present different positions which can be easily functionalized
by introducing new functional groups. This feature and their
easy synthetic accessibility make sulfonamide derivatives suit-
able candidates to design biotin-tagged probes for MMPs. As
zinc binding groups (ZBG), the carboxylic acid was selected
despite its relatively weak affinity for the metal ion (36-38).
The choice of a carboxylic acid to replace the most commonly
used hydroxamic acid warrants higher stability of the inhibitor
under physiological conditions (39) and provides better bio-
availability (40).
In all MMPs, the flexibility of the protein loops forming the
active site makes these enzymes able to modify the shape of
the catalytic pocket to accommodate ligands with different
structures (41-44). In particular, analyzing the structures
available on the protein data bank, it is apparent that the volume
of the S1′ cavity can be changed to host ligands bearing
lipophilic groups of different size. However, in MMP-1 and
MMP-7 the S1′ cavity is narrow as well as short “trucked”
(MMP-7) such that bulky groups generally do not fit. Therefore,
in order to probe all members of the MMP family, two scaffolds,
bearing either a linear biphenyl moiety or a shorter methox-
yphenyl group, were considered as possible bases for the
synthesis of BTIs.
Among all the scaffolds evaluated, molecules 1 and 2 (Figure
1) were selected for their low Ki values against five different
MMPs (see Table 1). Noteworthy, the two scaffolds exhibit a
sizably different selectivity and affinity for the MMPs chosen.
In particular, inhibitor 1, due to the presence of a biphenyl
moiety on the sulfonamide sulfur, showed inhibition constants
in the nanomolar range. Only for MMP-1 and MMP-7 was the
affinity in the low-micromolar range due to the relatively slim
size of the S1′ pocket (45). Although still good, 2 is a weaker
MMP inhibitor with micromolar values of Ki for all the MMPs
tested.
Matrix metalloproteinase 12 (MMP-12) performs proteolysis
of several ECM components including elastin, laminin, and type
IV collagen. The stability of the active MMP-12 catalytic
domain in the presence of weak inhibitors, the relatively large
S1′ pockets, and the high yield of the 15N-enriched protein in
minimal medium make this enzyme an ideal model to evaluate
BTI candidates.
To explore the binding mode of the two scaffolds and to
properly design the biotin tag derivatives, the two inhibitors
were soaked in crystals of MMP-12 and the structure of the
complexes solved by X-ray crystallography. Analysis of the
crystal structures (see Figure 2) revealed that the inhibitors share
a similar binding mode, with the catalytic zinc ion coordinated
by the oxygens of the free carboxylate, the sulfonyl oxygen
H-bonded with the NH of the Ala 182, and the liphophilic
Figure 1. Structure of the selected scaffolds 1 and 2.
Figure 2. X-ray structure of the catalytic domain of MMP-12
complexed with 1 (A) and with 2 (B). Only the ligand binding site is
shown for clarity.
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groups nested inside the S1′ pocket. The structural analysis
accounts for the larger affinity of 1 for MMP-12 with respect
to scaffold 2, as observed in the enzymatic assays. Indeed, in
the MMP-12-1 complex, larger hydrophobic interactions result
from the larger surface-to-surface contact area due to the
presence of the biphenyl moiety. More important for the biotin
tag inhibitor design was the solvent exposure of the sulfonamide
nitrogen revealed by the crystal structures for both ligands. These
structural data address the question related to the identification
of the position where the tag can be inserted without spoiling
the binding affinity.
A further critical point in developing efficient biotinylated
probes for in vivo and in vitro applications is represented by
the choice of a suitable linker able to prevent any steric clashes
between avidin and the target biomolecule. While a too-short
spacer may impair the ability of the probe to bind both MMP
and avidin, the use of a too-long spacer could affect the
bioavailability, stability, and solubility of the whole molecule.
In particular, a too-long linker can increase the susceptibility
of the probe to be split by enzymes such as the biotinidase that
can degrade the molecule in vivo (46). Once more, the
availabilityof thethree-dimensionalstructureofbothavidin-biotin
complex (present in protein data bank, PDB code: 2avi) and
1-MMP-12 complex has provided the background information
needed for a rational molecular design of the biotin-tagged
inhibitors we conceived (see Supporting Information).
A fourteen-membered spacer was designed to link the biotin
residue to the carboxylic-methyl ester sulfonamide 3 (Scheme
1), that is the shorter, synthetically convenient linker allowing
the probe to bind both MMP and avidin binding sites.
The biotinylated inhibitor 4 was obtained as shown in Scheme
1. Biotin was first reacted under known procedures (46) with
the N-Boc-1,6-diaminohexane 5 to give the amido derivative 6
which, after removal of tert-butyloxy carbonyl protecting group,
gave the trifluoroacetylammonium salt 7. Compound 7 was
treated with the bromosulfonamide 8 in the presence of cesium
Table 1. Inhibition Constants (Ki) of the Considered Compounds toward the Considered MMPs
compound MMP-1 MMP-7 MMP-8 MMP-12 MMP-13
1 18 ( 2 µM 56 ( 6 µM 31 ( 4 nM 25 ( 2 nM 108 ( 12 nM
2 302 ( 25 µM 80 ( 9 µM 4.6 ( 5 µM 1.4 ( 0.2 µM 2.6 ( 0.3 µM
4 25 ( 3 µM 450 ( 50 nM 4 ( 0.5 nM 5 ( 0.6 nM 0.7 ( 0.2 nM
10 295 ( 40 µM 73 ( 7 µM 8 ( 1 µM 1.6 ( 0.2 µM 1.2 ( 0.1 µM
Scheme 1. Synthesis of BTI 4 and Bromosulfenamide 8
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hydroxide, in dimethylformamide as solvent, to give the
diastereomerically pure ester 9 in 55% yield. Removal of the
methyl ester with lithium hydroxide/water from the latter
afforded BTI 4 as a diastereomerically pure compound in 55%
yield (Scheme 1). Following the synthetic pathway reported for
4, the biotin-tagged MMP-12 inhibitor 10 was also prepared
from 7 and bromosulfonamide 11, as a diasteromerically pure
compound (Scheme 2).
The affinity properties of the two BTI derivatives toward
the selected MMPs were first evaluated by fluorimetric assay
(see Supporting Information). The Ki values are reported in
Table 1. While BTI 4 had lower Ki values as compared to the
corresponding precursor 1, BTI 10 exhibited comparable affinity
with respect to its precursor 2. The micromolar Ki of BTI 10
for all the tested MMPs unambiguously demonstrated that the
latter is less interesting as a probe to detect these enzymes in
vivo, though it might be suitable to collect and purify MMPs
from biological samples. Conversely, BTI 4 exhibited a nano-
molar affinity for all the MMPs considered (including MMP-
7) except for MMP-1, for which the Ki was, however, still in
the low micromolar range. The molecular details for the
observed improved affinity were analyzed by investigating the
BTI 4 -MMP-12 complex.
Several attempts aimed at obtaining the X-ray structure of
the biotin tag inhibitors in complex with MMP-12, either by
soaking or cocrystallization, failed, probably for steric reasons
owing to the tag. Therefore, interaction of compound 1 and of
its biotin tag derivative 4 with the catalytic domain of MMP-
12 was further investigated following the chemical shift
perturbations on 15N-1H HSQC spectra using 15N-labeled
protein samples. The chemical shift is a sensitive indicator of
protein-ligand interactions and can be used to identify the
binding site when the resonance assignment is available (47).
The complete assignment of the catalytic domain of MMP-12
complexed with the weak inhibitor acetohydroxamic acid is
available in our laboratory. Increasing amounts of 1 and 4 were
added to 200 µM solutions of the protein up to an equimolar
concentration. Although several NH signals were shifted by
adding the inhibitors, as many as 134 and 129 cross-peaks
belonging to protein adducts with 1 and 4, respectively, were
easily reassigned. The intensity of signals belonging to NH
groups perturbed by the addition of the ligands decreased
linearly, while new cross-peaks corresponding to the BTI-bound
form of the protein appeared and gradually increased their
intensity, in agreement with the effect produced by a slow-
exchanging ligand.
The binding mode of ligands 1 and 4, respectively, was
analyzed and compared by reporting Garrett values [∆δ(NH)]
on a surface representation of the MMP-12 structure (Figure
3). As is evident from Figure 3, for both inhibitors, the region
with significant 15N-1H HSQC spectral perturbations involves
the catalytic pocket. The analysis of Garrett values rules out
relevant additive interactions of the biotinylated tail present in
BTI 4 with protein regions outside the catalytic pocket,
suggesting a different origin for the observed improved affinity.
In addition, a hypothetical binding mode with the biotinylated
tail of BTI 4 fitting in the S1′ cavity can be completely excluded
by the chemical shift perturbations on the 15N-1H HSQC spectra
that are similar for 1 and 4 as well as by the Ki values of the
BTI 10, which, although biotinylated, showed a low affinity
for the enzyme. Likely, extra interactions related to a better fit
of 4 into the active site of the enzyme become possible when
the fourteen-membered spacer is introduced on BTI 4. These
extra interactions are particularly evident for MMP-7 (Table 1)
where the affinity increases by 2 orders of magnitude upon the
introduction of the linker.
Although a high affinity for the target protein is a basic
requirement for the proposed bifunctional ligand to play its role,
only the ability of the latter to bind MMP and avidin
simultaneously could prove its real efficacy as effective BTI.
Scheme 2. Synthesis of BTI 10
Figure 3. Surface representation of the residues of the catalytic domain of MMP-12 affected by chemical shift perturbation upon the addition of
1 (A) and of 4 (B). Areas of interaction with significant 15N-1H HSQC spectra perturbations are colored-coded according to the Garret values.
Magenta, ∆δ(NH) > 0.1 ppm; Yellow, 0.1 > ∆δ(NH) > 0.05; Cyan, 0.05 > ∆δ(NH) > 0.03.
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Two different approaches based on NMR spectroscopy and on
surface plasmon resonance (SPR) were followed to demonstrate
the ternary Avidin-BTI-MMP interaction. Several NMR pa-
rameters are strongly influenced by the molecular weight and
by the dynamical properties of the investigated macromolecules.
Classical NMR experiments such as 15N-1H HSQC usually
performed to investigate biomolecules up to 30-40 kDa are
inefficient for larger systems due to the fast transverse relaxation
rate that broaden the signals beyond the detection threshold (48).
Therefore, NH resonances can act as probes to investigate the
formation of large protein-protein complexes (49). In the
present case, the evolution of the NH signals of the 15N MMP-
12 catalytic domain complexed with the BTI 4 in 15N-1H HSQC
spectra was exploited to monitor the interaction with nonlabeled
avidin, given that the binding of the biotin moiety to one of the
four binding sites on the tetrameric avidin should provide a 87
kDa complex. Since multiple binding for each avidin molecule
may occur, even larger protein complexes are expected in
solution. As shown in Figure 4 (panel D), the addition of an
equimolar solution of the 65 kDa avidin to a solution of the
15N-labeled catalytic domain of MMP-12 complexed with the
BTI 4 caused the complete disappearance of all NH cross-peaks
without any precipitation of the sample.
To exclude the presence of aspecific protein-protein interac-
tions, avidin was added to a solution containing 200 µM of
NNGH-inhibited-MMP-12 catalytic domain: in this case, no
changes were detected in the HSQC spectra. Therefore, we can
reasonably conclude that the strong protein-protein interaction,
monitored by the 15N-1H HSQC experiments, is mediated by
the BTI 4 which is able to bind MMP-12 and avidin and to
prevent, at the same time, an extensive reciprocal reorientation
of the complex subunits. Although NMR data allowed us to
ascertain that 4 does bind both avidin and MMP-12 simulta-
neously, the micromolar concentrations used for these experi-
ments do not provide information on how this simultaneous
interaction may affect the nanomolar affinity of the inhibitor to
MMP-12. Indeed, possible steric effects related to the presence
of the hemopexin domain need to be evaluated to understand
the real binding capability of the probe toward functionally
active enzymes (50). In this respect, the availability of the active
full-length MMP-12 allowed us to ascertain the efficiency of
the biotinylated inhibitor to bind simultaneously avidin and the
physiologically active enzyme and to quantify the effect of the
hemopexin domain on the affinity constant.
Surface plasmon resonance (SPR) is widely applied to
investigate protein-protein and protein-ligand interactions.
Information on affinity constant, on binding kinetics, as well
as on binding enthalpy can be quickly obtained by using small
Figure 4. 15N-1H HSQC spectrum of MMP-12 catalytic domain in the absence (A) and in the presence (B) of compound 4 (equimolar concentration).
The two spectra are superimposed to highlight the cross-peak shifts (C). The ternary complex formation Avidin-BTI-MMP is seen in panel D where
most of the cross-peaks disappeared.
Figure 5. SDS PAGE analysis of the fractions shows an effective
chromatographic separation of MMP-12 and carbonic anhydrase loaded
on a monomeric avidin-bound column.
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amounts of protein samples. In particular, the sensitivity of the
SPR technique permits the investigation of high-affinity interac-
tions and monitoring the formation of ternary complexes. SPR
analysis was carried out using a ProteOn XPR36 parallel array
biosensor equipped with avidin sensor chips (NLC). This chip
has an avidin-coated surface that can be used to immobilize
biotinylated molecules and macromolecules (51). In our study,
BTI 4 was immobilized on channels 1-5 of the chip by injecting
PBS-T buffered solutions of the biotinylated molecule at
different concentrations. The sixth channel was left blank. The
assay was performed by injecting solutions of the full-length
MMP-12 on the chip channels and fitting the sensorgrams at
four different concentrations. The measured KD (4.6 ( 0.3 nM)
(Supporting Information Figure S2) was comparable to the
fluorimetric Ki measured for 4 vs the isolated catalytic domain
of MMP-12 (BTI 4-MMP-12 complex).
The employment of bifuctional ligand BTI 4 for the selective
collection of matrix metalloproteinases from biological fluids
has been evaluated by using a monomeric avidin-bound column
(Pierce). An amount of 2.5 mg of BTI 4 was dissolved in 8.1
mL of Tris-buffer, and the solution (50 uL) was mixed with
the same volume of an equimolar sample of MMP-12 (0.4 mM)
dissolved into Tris buffer; 25 uL of the mixture so obtained
was added to 50 uL of a solution of carbonic anhydrase from
erythrocytes (0.1 mM in Tris-buffer). A monomeric avidin-
bound column (0.6 mL of settled gel) was loaded with the
solution of BTI 4, MMP-12, and carbonic anhydrase; then, it
was first eluted with 1.4 mL of Tris-buffer and subsequently
with a solution of NNGH (1 mM, Tris buffer). Relying on the
strong avidin-biotin interaction, the column blocked BTI
4-MMP-12 complex, while carbonic anhydrase was completely
washed out. Addition of nanomolar inhibitor NNGH displaced
BTI 4 complexed to MMP-12, and the latter was so eluted and
separated from carbonic anhydrase (Figure 5).
In summary, the present structure-based design led to the
development of a potent biotin probe to bind matrix metallo-
proteinases for possible application in vitro and in vivo. The
structural requirements defined through the analysis of the X-ray
structures allowed selection of the position on the scaffold where
the linker could be introduced and the correct length of the
biotinylated tag. As defined by NMR analysis, the origin of the
larger affinity observed for BTI 4 is a better fit of the selected
scaffold in the catalytic pocket rather than additive interactions
of the linker on the protein surface. The enzymatic assay
demonstrated a nanomolar to low micromolar (MMP-1) affinity
of 4 not only for MMP-12 but also for all the MMPs
investigated. Furthermore, the evolution of the 15N-1H HSQC
spectra upon the addition of unlabeled avidin to solution of 15N
MMP-12 clearly showed that the fourteen-member spacer used
to link the biotin unit to carboxylic aryl sulfonamide inhibitor
1 ensures the simultaneous binding of the two proteins without
permitting large interprotein mobility. SPR analyses clearly
showed the ability of 4 to bind the functional active enzyme
MMP-12 and avidin side-by-side. This simultaneous interaction
did not affect negatively the nanomolar affinity of inhibitor 4
for MMP-12, given that the SPR data nicely reproduced the
fluorimetric values measured for the BTI 4-MMP-12 complex.
ACKNOWLEDGMENT
This work was supported by EC (Projects: MEST-CT-2004-
504391, Integrated Project - SPINE2-COMPLEXES no 031220,
Nano4Drugs no LSHB-CT-2005-019102; SFMET no 201640),
by MIUR (FIRB Prot. RBLA032ZM7; FIRB Prot. RBIP06LSS2),
Ente Cassa di Risparmio di Firenze, Genexpress.
Supporting Information Available: Protein cloning, expres-
sion and purification, X-ray data, details of fluorimetric assays
and synthesis and characterization of compounds 1-3 and 11
are included. This material is available free of charge via the
Internet at http://pubs.acs.org.
LITERATURE CITED
(1) Giepmans, B. N. G., Adams, S. R., Ellisman, M. H., and Tsien,
R. Y. (2006) The fluorescent toolbox for assessing protein
location and function. Science 312, 217–224.
(2) Blundell, T. L., Jhoti, H., and Abell, C. (2002) High-throughput
crystallography for lead discovery in drug design. Nat. ReV. Drug
Discoery 1, 45–54.
(3) Johnson, S. L., and Pellecchia, M. (2006) Structure- and
fragment-based approaches to protease inhibition. Curr. Top.
Med. Chem. 6, 317–329.
(4) Heckmann, D., Meyer, A., Marinelli, L., Zahn, G., Stragies,
R., and Kessler, H. (2007) Probing integrin selectivity: rational
design of highly active and selective ligands for the R 51 and
R53 integrin receptor. Angew. Chem., Int. Ed. 46, 3571–3574.
(5) Jahnke, W., Blommers, M. J., Fernandez, C., Zwingelstein, C.,
and Amstutz, R. (2005) Strategies for the NMR-based identifica-
tion and optimization of allosteric protein kinase inhibitors.
ChemBioChem 6, 1607–1610.
(6) Page-McCaw, A., Ewald, A. J., and Werb, Z. (2007) Matrix
metalloproteinases and the regulation of tissue remodelling. Nat.
ReV. Mol. Cell Biol. 8, 221–233.
(7) Parks, W. C., Wilson, C. L., and Lopez-Boado, Y. S. (2004)
Matrix metalloproteinases as modulators of inflammation and
innate immunity. Nat. ReV. Immunol. 4, 617–629.
(8) D’Alessio, S., Fibbi, G., Cinelli, M., Guiducci, S., Del Rosso,
A., Margheri, F., Serrati, S., Pucci, M., Kahaleh, B., Fan, P. S.,
Annunziato, F., Cosmi, L., Liotta, F., Matucci-Cerinic, M., and
Del Rosso, M. (2004) Matrix metalloproteinase 12-dependent
cleavage of urokinase receptor in systemic sclerosis microvas-
cular endothelial cells results in impaired angiogenesis. Arthritis
Rheum. 50, 3275–3285.
(9) Boire, A., Covic, L., Agarwal, A., Jacques, S., Sherifl, S., and
Kuliopulos, A. (2005) PAR1 is a matrix metalloprotease-1
receptor that promotes invasion and tumorigenesis of breast
cancer cells. Cell 120, 303–313.
(10) Fragai, M., and Nesi, A. (2007) Substrate specificities of matrix
metalloproteinase 1 in PAR-1 exodomain proteolysis. ChemBio-
Chem 8, 1367–1369.
(11) Knauper, V., Will, H., Lopez-Otin, C., Smith, B., Atkinson,
S. J., Stanton, H., Hembry, R. M., and Murphy, G. (1996)
Cellular mechanisms for human procollagenase-3 (MMP-13)
activation. Evidence that MT1-MMP (MMP-14) and gelatinase
a (MMP-2) are able to generate active enzyme. J. Biol. Chem.
271, 17124–17131.
(12) Morrison, C. J., and Overall, C. M. (2006) TIMP Independence
of matrix metalloproteinase (MMP)-2 activation by membrane
type 2 (MT2)-MMP is determined by contributions of both the
MT2-MMP catalytic and hemopexin C domains. J. Biol. Chem.
281, 26528–26539.
(13) Ra, H. J., and Parks, W. C. (2007) Control of matrix
metalloproteinase catalytic activity. Matrix Biol. 26, 587–596.
(14) Overall, C. M., Tam, E., McQuibban, G. A., Morrison, C.,
Wallon, U. M., Bigg, H. F., King, A. E., and Roberts, C. R.
(2000) Domain interactions in the gelatinase A · TIMP-2 · MT1-
MMP activation complex: the ectodomain of the 44-kDa form
of membrane type-1 matrix metalloproteinase does not modulate
gelatinase A activation. J. Biol. Chem. 275, 39497–39506.
(15) Fingleton, B. (2007) Matrix metalloproteinases as valid clinical
targets. Curr. Pharm. Des. 13, 333–346.
(16) Skiles, J. W., Gonnella, N. C., and Jeng, A. Y. (2004) The
design, structure, and clinical update of small molecular weight
matrix metalloproteinase inhibitors. Curr. Med. Chem. 11, 2911–
2977.
(17) Egeblad, M., and Werb, Z. (2002) New functions for the
matrix metalloproteinases in cancer progression. Nat. ReV.
Cancer 2, 161–174.
Biotin-Tagged Probes for MMP Expression and Activation Bioconjugate Chem., Vol. 20, No. 4, 2009 725
(18) Bremer, C., Tung, C. H., Bogdanov, A., and Weissleder, R.
(2002) Imaging of differential protease expression in breast
cancers for detection of aggressive tumor phenotypes. Radiology
222, 814–818.
(19) Lepage, M., Dow, W. C., Melchior, M., You, Y., Fingleton,
B., Quarles, C. C., Pepin, C., Gore, J. C., Matrisian, L. M., and
McIntyre, J. O. (2007) Non invasive detection of matrix
metalloproteinase activity in vivo using a novel magnetic
resonance imaging contrast agent with a solubility switch. Mol.
Imaging 6, 393–403.
(20) David, A., Steer, D., Bregant, S., Devel, L., Makaritis, A.,
Beau, F., Yiotakis, A., and Dive, V. (2007) Cross-linking yield
variation of a potent matrix metalloproteinase photoaffinity probe
and consequences for functional proteomics. Angew. Chem., Int.
Ed. 46, 3275–3277.
(21) Saghatelian, A., Jessani, N., Joseph, A., Humphrey, M., and
Cravatt, B. F. (2004) Activity-based probes for the proteomic
profiling of metalloproteases. Proc. Natl. Acad. Sci. U.S.A. 101,
10000–10005.
(22) Bremer, C., Tung, C. H., and Weissleder, R. (2001) In vivo
molecular target assessment of matrix metalloproteinase inhibi-
tion. Nat. Med. 7, 743–748.
(23) Faust, A., Waschkau, B., Waldeck, J., Holtke, C., Breyholz,
H. J., Wagner, S., Kopka, K., Heindel, W., Schafers, M., and
Bremer, C. (2008) Synthesis and evaluation of a novel fluorescent
photoprobe for imaging matrix metalloproteinases. Bioconjugate
Chem. 19, 1001–1008.
(24) Wagner, S., Breyholz, H. J., Law, M. P., Faust, A., Holtke,
C., Schroer, S., Haufe, G., Levkau, B., Schober, O., Schafers,
M., and Kopka, K. (2007) Novel fluorinated derivatives of the
broad-spectrum MMP inhibitors N-hydroxy-2(R)-[[(4-methox-
yphenyl)sulfonyl](benzyl)- and (3-picolyl)-amino]-3-methyl-bu-
tanamide as potential tools for the molecular imaging of activated
MMPs with PET. J. Med. Chem. 50, 5752–5764.
(25) Wagner, S., Breyholz, H. J., Faust, A., Holtke, C., Levkau,
B., Schober, O., Schafers, M., and Kopka, K. (2006) Molecular
imaging of matrix metalloproteinases in vivo using small
molecule inhibitors for SPECT and PET. Curr. Med. Chem. 13,
2819–2838.
(26) Uttamchandani, M., Wang, J., Li, J. Q., Hu, M. Y., Sun, H. Y.,
Chen, K. Y. T., Liu, K., and Yao, S. Q. (2007) Inhibitor
fingerprinting of matrix metalloproteases using a combinatorial
peptide hydroxamate library. J. Am. Chem. Soc. 129, 7848–7858.
(27) Bertini, I., Calderone, V., Fragai, M., Luchinat, C., and
Maletta, M. (2006) Snapshots of the reaction mechanism of
matrix metalloproteinases. Angew. Chem., Int. Ed. 45, 7952–
7955.
(28) Bertini, I., Calderone, V., Fragai, M., Luchinat, C., Mangani,
S., and Terni, B. (2003) X-ray structures of binary and ternary
enzyme-product-inhibitor complexes of matrix metalloprotein-
ases. Angew. Chem., Int. Ed. 42, 2673–2676.
(29) Bertini, I., Calderone, V., Fragai, M., Luchinat, C., Mangani,
S., and Terni, B. (2004) Crystal structure of the catalytic domain
of human matrix metalloproteinase 10. J. Mol. Biol. 336, 707–
716.
(30) Bertini, I., Calderone, V., Fragai, M., Giachetti, A., Loconte,
M., Luchinat, C., Maletta, M., Nativi, C., and Yeo, K. (2007)
Exploring the subtleties of drug-receptor interactions: the case
of matrix metalloproteinases. J. Am. Chem. Soc. 129, 2466–2475.
(31) Bertini, I., Fragai, M., Lee, Y.-M., Luchinat, C., and Terni,
B. (2004) Paramagnetic metal ions in ligand screening: The CoII
matrix metalloproteinase 12. Angew. Chem., Int. Ed. 43, 2254–
2256.
(32) Calderone, V., Fragai, M., Luchinat, C., Nativi, C., Richichi,
B., and Roelens, S. (2006) A high-affinity carbohydrate-
containing inhibitor of matrix metalloproteinases. ChemMedChem
1, 598–601.
(33) Bertini, I., Fragai, M., Giachetti, A., Luchinat, C., Maletta,
M., Parigi, G., and Yeo, K. J. (2005) Combining in silico tools
and NMR data to validate protein-ligand structural models:
application to matrix metalloproteinases. J. Med. Chem. 48,
7544–7559.
(34) Fragai, M., Nativi, C., Richichi, B., and Venturi, C. (2005)
Design in silico, synthesis and binding evaluation of a carbo-
hydrate-based scaffold for structurally novel inhibitors of matrix
metalloproteinases. ChemBioChem 6, 1345–1349.
(35) Mannino, C., Nievo, M., Machetti, F., Papakyriakou, A.,
Fragai, M., and Guarna, A. (2006) Synthesis of bicyclic
molecular scaffolds (BTAa): An investigation towards new
selective MMP-12 inhibitors. Bioorg. Med. Chem. 14, 7392–
7403.
(36) Agrawal, A., Romero-Perez, D., Jacobsen, J. A., Villarreal,
F. J., and Cohen, S. M. (2008) Zinc-binding groups modulate
selective inhibition of MMPs. ChemMedChem 3, 812–820.
(37) Puerta, D. T., and Cohen, S. M. (2004) A bioinorganic
perspective on matrix metalloproteinase inhibition. Curr. Top.
Med. Chem. 4, 1551–1573.
(38) Pikul, S., Ohler, N. E., Ciszewski, G., Laufersweiler, M. C.,
Almstead, N. G., De, B., Natchus, M. G., Hsieh, L. C., Janusz,
M. J., Peng, S. X., Branch, T. M., King, S. L., Taiwo, Y. O.,
and Mieling, G. E. (2001) Potent and selective carboxylic acid-
based inhibitors of matrix metalloproteinases. J. Med. Chem. 44,
2499–2502.
(39) Wang, X. Q., Choe, Y. C., Craik, C. S., and Ellman, J. A.
(2002) Design and synthesis of novel inhibitors of gelatinase B.
Bioorg. Med. Chem. Lett. 12, 2201–2204.
(40) Auge, F., Hornebeck, W., Decarme, M., and Laronze, J. Y.
(2003) Improved gelatinase a selectivity by novel zinc binding
groups containing galardin derivatives. Bioorg. Med. Chem. Lett.
13, 1783–1786.
(41) Bertini, I., Calderone, V., Cosenza, M., Fragai, M., Lee, Y.-
M., Luchinat, C., Mangani, S., Terni, B., and Turano, P. (2007)
Solution structure of inhibitor-free human metalloelastase (MMP-
12) indicates an internal conformational adjustment. J. Mol. Biol.
374, 1333–1344.
(42) Bhaskaran, R., Palmier, M. O., Bagegni, N. A., Liang, X. Y.,
and Van Doren, S. R. (2007) Solution structure of inhibitor-free
human metalloelastase (MMP-12) indicates an internal confor-
mational adjustment. J. Mol. Biol. 374, 1333–1344.
(43) Devel, L., Rogakos, V., David, A., Makaritis, A., Beau, F.,
Cuniasse, P., Yiotakis, A., and Dive, V. (2006) Development of
selective inhibitors and substrate of matrix metalloproteinase-
12. J. Biol. Chem. 281, 11152–11160.
(44) Tochowicz, A., Maskos, K., Huber, R., Oltenfreiter, R., Dive,
V., Yiotakis, A., Zanda, M., Bode, W., and Goettig, P. (2007)
Crystal structures of MMP-9 complexes with five inhibitors:
contribution of the flexible Arg424 side-chain to selectivity. J.
Mol. Biol. 371, 989–1006.
(45) Lovejoy, B., Welch, A. R., Carr, S., Luong, C., Broka, C.,
Hendricks, R. T., Campbell, J. A., Walker, K. A. M., Martin,
R., Van Wart, H., and Browner, M. F. (1999) Crystal structures
of MMP-1 and -13 reveal the structural basis for selectivity of
collagenase inhibitors. Nat. Struct. Biol. 6, 217–221.
(46) Sabatino, G., Chinol, M., Paganelli, G., Papi, S., Chelli, M.,
Leone, G., Papini, A. M., De Luca, A., and Ginanneschi, M.
(2003) A new biotin derivative-DOTA conjugate as a candidate
for pretargeted diagnosis and therapy of tumors. J. Med. Chem.
46, 3170–3173.
(47) Canales-Mayordomo, A., Fayos, R., Angulo, J., Ojeda, R.,
Martin-Pastor, M., Nieto, P. M., Martin-Lomas, M., Lozano, R.,
Gimenez-Gallego, G., and Jimenez-Barbero, J. (2006) Backbone
dynamics of a biologically active human FGF-1 monomer,
complexed to a hexasaccharide heparin-analogue, by 15N NMR
relaxation methods. J. Biomol. NMR 35, 225–239.
(48) Pellecchia, M., Sebbel, P., Hermanns, U., Wuthrich, K., and
Glockshuber, R. (1999) Pilus chaperone FimC-adhesin FimH
interactions mapped by TROSY-NMR. Nat. Struct. Biol. 6, 336–
339.
(49) D’Silva, L., Ozdowy, P., Krajewski, M., Rothweiler, U., Singh,
M., and Holak, T. A. (2005) Monitoring the effects of antagonists
726 Bioconjugate Chem., Vol. 20, No. 4, 2009 Dragoni et al.
on protein-protein interactions with NMR spectroscopy. J. Am.
Chem. Soc. 12713220–13226.
(50) Bertini, I., Calderone, V., Fragai, M., Jaiswal, R., Luchinat,
C., Melikian, M., Mylonas, E., and Svergun, D. (2008) Evidence
of reciprocal reorientation of the catalytic and hemopexin-like
domains of full-length MMP-12. J. Am. Chem. Soc. 130, 7011–
7021.
(51) Bravman, T., Bronner, V., Lavie, K., Notcovich, A., Papalia,
G. A., and Myszka, D. G. (2006) Exploring “one-shot” kinetics
and small molecule analysis using the ProteOn XPR36 array
biosensor. Anal. Biochem. 358, 281–288.
BC8003827
Biotin-Tagged Probes for MMP Expression and Activation Bioconjugate Chem., Vol. 20, No. 4, 2009 727
